

Photocatalytic Synthesis of 2-Oxabicyclo[2.1.1]hexanes: Cobalt-Enhanced Efficiency

Si-Yuan Tang^{+, [a]} Zhan-Jie Wang^{+, [a]} Jin-Jiao Wu,^[a] Zhi-Xi Xing,^[a] Ze-Yi
Du,^[b] and Huan-Ming Huang^{[a]*}

^aSchool of Physical Science and Technology, ShanghaiTech University,
Shanghai 201210, China

^bDepartment of Medicinal Chemistry, School of Pharmacy, Fudan
University, No. 826 Zhangheng Road, Shanghai 201203, China

+ equal contribution

*Correspondence author. Email: huanghm@shanghaitech.edu.cn

SUPPORTING INFORMATION

Table of Contents

1	General Experimental	S 3
1.1	Data Analysis.....	S 3
2	Synthesis of Starting Materials	S 5
2.1	General Procedure A.....	S 6
2.2	General Procedure B.....	S 7
2.3	Experimental Procedures and Spectral Characterization of the Starting Material.....	S 7
3	Synthesis of Desired Compounds.....	S 11
3.1	General Procedure C: Preparation of Desired Compounds.....	S 11
3.2	Experimental Procedures and Spectral Characterization of the Desired Products.....	S 11
4	Mechanistic Studies.....	S 43
4.1	Radical cation trapping experiment.....	S 43
4.2	Radical trapping experiment.....	S 44
4.3	Ketyl Radical-trapping Experiment.....	S 48
4.4	UV-Vis Absorption Spectra Analysis.....	S 49
4.5	Stern-Volmer Luminescence Quenching Analysis.....	S 49
4.6	Quantum Yield Experiment.....	S 51
5	Gram-scale experiment.....	S 54
6	Synthetic Transformation.....	S 55
7	Physicochemical Property Assessment	S 61
8	Phrenological Property Assessment.....	S 62
9	Docking Analysis	S 65
10	X-Ray Structure of Compound 33.....	S 66
11	Unsuccessful Cases.....	S 67
12	NMR Spectra of Starting Materials.....	S 68
13	NMR Spectra of Desired Compounds.....	S 74
14	References.....	S 149

1 General Experimental

All experiments were performed in oven-dried glassware under nitrogen unless otherwise stated. All reagents were purchased from Alfa Aesar, Adamas, Accela, Bidepharm, Energy chemical, J&K chemical, Macklin, TCI, Leyan and used without further purification, unless otherwise stated. Dry solvents were purchased from J&k chemical (Extra Dry, H₂O <10 ppm) in J&KSeal® bottles, stored under molecular sieves and used as received or obtained from commercial sources. Dichloromethane, toluene, diethyl ether, THF were purified by passage through an activated alumina column under nitrogen. Thin-layer chromatography (TLC) analysis of reaction mixtures were performed using Huanghai silica gel HSGF254 TLC plates and Leyan HPTLC Silica Gel 60 GF254, and visualized under UV or by staining with ceric ammonium molybdate or potassium permanganate.

1.1 Data Analysis

Nuclear magnetic resonance (NMR) spectra were recorded using Bruker Avance III HD spectrometer (FT, 400, 500 or 600 MHz for ¹H, 101, 126 or 150 MHz for ¹³C). All spectral data were acquired at 295 K. Chemical shifts (δ) are quoted in parts per million (ppm) against tetramethylsilane (TMS, δ = 0.00 ppm). The following residual solvent signals were used as references for ¹H and ¹³C NMR spectra: CDCl₃, δ H 7.26 ppm, δ C 77.16 ppm, δ C calibrated using absolute referencing to the ¹H spectrum). ¹⁹F-NMR spectra were calibrated using absolute referencing to the ¹H-NMR spectrum, as suggested by IUPAC. Coupling constants (*J*) are reported in Hertz (Hz) to the nearest 0.1 Hz. The multiplicity abbreviations used (or combinations thereof) are: s = singlet, d = doublet, t = triplet, q = quartet, hept = heptet, m = multiplet. High-resolution mass spectra (HRMS) were obtained from the Agilent Technologies 6230 TOF LC/MS spectrometer in electrospray ionization (ESI⁺) mode. Ultraviolet-visible (UV-vis) absorption spectra were recorded by an AgilentCary 3000 UV-vis spectrophotometer at 25 °C. Stern-Volmer luminescence quenching analyses were conducted using an Edinburgh

Instruments FS5 spectrometer. X-Ray structure analyses were performed using a Bruker D8 Venture X-ray single crystal diffractometer.

2 Synthesis of Starting Materials

Compound 1




Figure S1. Chemical structures of compound 1

Compound 2: Alkyl




Figure S2. Chemical structures of alkyl compound 2




Figure S3. Chemical structures of aryl compound 2





Figure S4. Chemical structures of drug derivatives starting material 75-77

Some compounds were synthesized according to published literature (see General Procedure A for compound **2y**, **2aa**, **2ad** and **2ae**, General Procedure B for compound **76** and **77**).^[1,2] Compound **1**, **2q**, **2v**, **2w**, **2x**, **2z**, **2ab**, **2ac** and **75** were synthesized according to published literatures and all analytical data matched the report.^[1,3-6] Other reagents were purchased from Alfa Aesar, Adamas, Accela, Bidepharm, Energy chemical, J&K chemical, Macklin, TCI, Leyan and used directly without further purification.

2.1 General Procedure A




Step1: Butane-1,4-diol (25 mmol) was dissolved in DCM (20 mL). Corresponding acid (5 mmol mmol), EDCl·HCl (7.5 mmol) and DMAP (1 mmol) were added under nitrogen atmosphere. The mixture was stirred for 12 hours under nitrogen atmosphere at RT. The reaction mixture was quenched with H₂O (40 mL) and extracted with EtOAc (3 × 40 mL). The organic phases were combined, dried over

NaSO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with indicated solvent system to give intermediate S1.


Step2: Intermediate S1 was dissolved in DCM (0.25 M). Dess-Martin reagent (1.2 eq.) was added under nitrogen atmosphere. The mixture was stirred for 12 hours under nitrogen atmosphere at RT. The reaction mixture was quenched with saturated NaHCO₃ aqueous solution (40 mL) and extracted with EtOAc (3 × 40 mL). The organic phases were combined, dried over NaSO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with indicated solvent system to give the desired compound.

2.2 General Procedure B



Ester compound (0.5 mmol) was dissolved in a mixture of THF, MeOH and H₂O (8/2/2 mL). NaOH (60 mg, 1.5 mmol) was added under nitrogen atmosphere. The mixture was stirred for 6 hours under nitrogen atmosphere at 50 °C. The reaction mixture was quenched with 2 M HCl aqueous solution (20 mL) and extracted with EtOAc (3 × 20 mL). The organic phases were combined, dried over NaSO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with indicated solvent system to give the desired compound.

2.3 Experimental Procedures and Spectral Characterization of the Starting Material




2y was synthesized according to the general procedure A and purified by flash column chromatography (silica gel), eluting with 20% EtOAc in PE to afford the title compound as a colourless oil (1.27 g, 3.92 mmol, 78% over 2-steps).

R_f = 0.5 (40% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 9.79 (t, J = 1.4 Hz, 1H), 8.09 – 8.02 (m, 2H), 7.71 – 7.67 (m, 2H), 7.67 – 7.60 (m, 2H), 7.47 (dd, J = 8.4, 6.8 Hz, 2H), 7.44 – 7.38 (m, 1H), 4.16 (t, J = 6.3 Hz, 2H), 3.35 (t, J = 6.5 Hz, 2H), 2.78 (t, J = 6.5 Hz, 2H), 2.61 – 2.53 (m, 2H), 1.99 (app. p, J = 6.8 Hz, 2H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 201.5, 197.8, 173.0, 146.1, 139.9, 135.3, 129.1 (2C), 128.8 (2C), 128.4, 127.4 (3C), 63.7, 40.6, 33.5, 28.3, 21.4 ppm.

HRMS (ESI) calculate: $\text{C}_{20}\text{H}_{21}\text{O}_4^+$ ($\text{M}+\text{H}$) $^+$: 325.1434, found: 325.1431.




2aa was synthesized according to the general procedure A and purified by flash column chromatography (silica gel), eluting with 20% EtOAc in PE to afford the title compound as a colourless oil (0.91 g, 3.64 mmol, 73% over 2-steps).

R_f = 0.6 (40% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 9.81 (t, J = 1.3 Hz, 1H), 7.98 (dd, J = 7.8, 1.7 Hz, 1H), 7.62 – 7.52 (m, 1H), 7.36 – 7.29 (m, 1H), 7.10 (dd, J = 8.1, 1.2 Hz, 1H), 4.31 (t, J = 6.4 Hz, 2H), 2.61 (td, J = 7.2, 1.2 Hz, 2H), 2.34 (s, 3H), 2.07 (t, J = 6.8 Hz, 2H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 201.2, 169.8, 164.4, 150.8, 134.1, 131.7, 126.2, 124.0, 123.2, 64.1, 40.5, 21.4, 21.2 ppm.

HRMS (ESI) calculate: $\text{C}_{13}\text{H}_{14}\text{O}_5^+$ ($\text{M}+\text{H}$) $^+$: 251.0914, found: 251.0911.




2ad was synthesized according to the general procedure A and purified by flash column chromatography (silica gel), eluting with 12% EtOAc in PE to afford the title compound as a colourless oil (1.02 g, 3.02 mmol, 60%).

R_f = 0.5 (30% EtOAc in PE)

¹H NMR (500 MHz, CDCl₃) δ 9.75 (t, *J* = 1.2 Hz, 1H), 8.10 (d, *J* = 2.4 Hz, 1H), 7.87 (dd, *J* = 7.7, 1.4 Hz, 1H), 7.57 – 7.50 (m, 1H), 7.50 – 7.43 (m, 1H), 7.40 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.38 – 7.33 (m, 1H), 7.02 (d, *J* = 8.5 Hz, 1H), 5.17 (s, 2H), 4.12 (t, *J* = 6.3 Hz, 2H), 3.62 (s, 2H), 2.55 – 2.47 (m, 2H), 2.00 – 1.91 (m, 2H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 201.3, 190.9, 171.4, 160.6, 140.5, 136.4, 135.6, 132.9, 132.5, 129.5, 129.4, 127.9, 127.7, 125.2, 121.2, 73.7, 64.0, 40.5, 40.2, 21.3 ppm.

HRMS (ESI) calculate: C₂₀H₁₉O₅⁺ (M+H)⁺: 339.1227, found: 339.1223.




2ae was synthesized according to the general procedure A and purified by flash column chromatography (silica gel), eluting with 5% EtOAc in PE to afford the title compound as a colourless oil (0.63 g, 2.94 mmol, 59%).

R_f = 0.5 (10% EtOAc in PE)

¹H NMR (500 MHz, CDCl₃) δ 9.78 (t, *J* = 1.3 Hz, 1H), 4.09 (t, *J* = 6.4 Hz, 2H), 2.56 – 2.49 (m, 2H), 2.37 – 2.30 (m, 1H), 2.00 – 1.92 (m, 2H), 1.61 – 1.51 (m, 2H), 1.40 (dd, *J* = 8.0, 5.3 Hz, 2H), 1.31 – 1.21 (m, 4H), 0.88 (app. t, *J* = 7.3 Hz, 6H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 201.4, 176.6, 63.1, 45.4, 40.6, 34.7 (2C), 21.5, 20.8 (2C), 14.1 (2C) ppm.

HRMS (ESI) calculate: C₁₂H₂₃O₃⁺ (M+H)⁺: 215.1642, found: 215.1642.




76 was synthesized according to the general procedure B and purified by flash column chromatography (silica gel), eluting with 3% MeOH in DCM to afford the title compound as a white solid (133 mg, 0.48 mmol, 95%).

R_f = 0.7 (8% MeOH in DCM)

¹H NMR (500 MHz, CDCl₃) δ 7.56 – 7.50 (m, 4H), 7.46 – 7.41 (m, 2H), 7.40 – 7.35 (m, 3H), 7.35 – 7.29 (m, 1H), 5.54 (s, 1H), 2.71 – 2.59 (m, 2H), 2.35 (s, 1H), 2.26 (dd, *J* = 8.1, 2.3 Hz, 1H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 176.0, 139.3, 136.8, 128.6 (3C), 128.3 (2C), 128.0, 126.8 (2C), 126.3 (2C), 87.1, 80.2, 54.6, 51.4, 39.8 ppm.

HRMS (ESI) calculate: $C_{18}H_{17}O_5^+$ (M+H)⁺: 281.1172, found: 281.1174.



77

77 was synthesized according to the general procedure B and purified by flash column chromatography (silica gel), eluting with 2% MeOH in DCM to afford the title compound as a white solid (130 mg, 0.47 mmol, 95%).

R_f = 0.8 (8% MeOH in DCM)

¹H NMR (400 MHz, MeOD) δ 8.03 (d, *J* = 2.1 Hz, 1H), 7.81 (dd, *J* = 8.0, 2.1 Hz, 1H), 7.69 (dd, *J* = 7.1, 1.8 Hz, 2H), 7.51 – 7.45 (m, 3H), 7.43 – 7.35 (m, 6H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 172.4, 142.3 (2C), 141.4, 141.0, 133.7, 132.5, 130.5, 130.1 (2C), 129.6 (2C), 129.2 (2C), 128.9 (2C), 128.3, 128.0 (2C) ppm.

HRMS (ESI) calculate: $C_{19}H_{15}O_2^+$ (M+H)⁺: 275.1067, found: 275.1066.

3 Synthesis of Desired Compounds

3.1 General Procedure C: Preparation of Desired Compounds


An oven-dried two-dram vials equipped with PTFE-coated stir bar and Teflon® septum were used. CoCl_2 (7.5 mol%), $\text{Mes}_2\text{Acr-}t\text{Bu}_2\text{BF}_4$ (**PC1**, 1 mol%), **1** (0.2 mmol, 2 eq.) and **2** (0.1 mmol, 1 eq.) were added into the vial and was dissolved in DCE (0.5 mL, 0.2 M). The vial was set to stir (500 rpm) and irradiated with a 30 W 450 nm blue LED lamp (approximate 3 cm away, with cooling fan to keep the reaction at room temperature). After 12 hours, the reaction mixture was transferred to a 100mL round-bottom flask and concentrated in vacuo. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with indicated solvent system to give the desired product.



Figure S5. Picture of 30 W 450 nm irradiator

3.2 Experimental Procedures and Spectral Characterization of the Desired Products

Methyl-3-phenethyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



3 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 3% EtOAc in PE to afford the title compound as a white solid (29 mg, 0.090 mmol, 90%).


R_f = 0.6 (10% EtOAc in PE)

¹H NMR (500 MHz, CDCl₃) δ 7.45 – 7.41 (m, 2H), 7.41 – 7.36 (m, 2H), 7.35 – 7.27 (m, 3H), 7.24 (d, *J* = 1.4 Hz, 2H), 7.22 – 7.18 (m, 1H), 4.34 (dd, *J* = 9.5, 3.6 Hz, 1H), 3.75 (s, 3H), 2.99 – 2.90 (m, 1H), 2.78 – 2.69 (m, 1H), 2.43 (d, *J* = 6.9 Hz, 1H), 2.39 – 2.31 (m, 2H), 2.26 (dd, *J* = 10.2, 7.7 Hz, 1H), 2.09 – 2.00 (m, 1H), 1.93 – 1.83 (m, 1H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 171.0, 142.1, 137.4, 128.6 (2C), 128.5 (4C), 128.4, 126.3 (2C), 126.0, 86.6, 79.7, 52.8, 52.1, 50.1, 42.1, 35.0, 32.3 ppm.

HRMS (ESI) calculate: C₂₁H₂₃O₃⁺ (M+H)⁺: 323.1642, found: 323.1641.

Methyl-3-(4-fluorophenethyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



4 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a pale-yellow oil. (18 mg, 0.053 mmol, 53%).

R_f = 0.6 (10% EtOAc in PE).


¹H NMR (500 MHz, CDCl₃) δ 7.44 – 7.30 (m, 5H), 7.23 – 7.17 (m, 2H), 7.00 – 6.94 (m, 2H), 4.30 (dd, *J* = 9.6, 3.5 Hz, 1H), 3.75 (s, 3H), 2.96 – 2.87 (m, 1H), 2.75 – 2.66 (m, 1H), 2.43 (d, *J* = 7.0 Hz, 1H), 2.34 (dd, *J* = 9.9, 7.1 Hz, 2H), 2.24 (dd, *J* = 10.3, 7.7 Hz, 1H), 2.05 – 1.97 (m, 1H), 1.89 – 1.79 (m, 1H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 170.8, 161.3 (d, *J* = 242.6 Hz), 137.5, 137.2, 129.86 (d, *J* = 7.8 Hz, 2C), 128.4 (2C), 128.3, 126.1 (2C), 115.11 (d, *J* = 21.0 Hz, 2C), 86.5, 79.3, 52.6, 52.0, 50.0, 42.0, 34.9, 31.4. ppm.

¹⁹F NMR (471 MHz, CDCl₃) δ -117.74 ppm.

HRMS (ESI) calculate: C₂₁H₂₂FO₃⁺ (M+H)⁺: 341.1547, found: 341.1545.

Methyl-3-(4-chlorophenethyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



5 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (20 mg, 0.0570 mmol, 57%).


R_f = 0.6 (10% EtOAc in PE).

$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.35 – 7.28 (m, 4H), 7.27 – 7.23 (m, 1H), 7.20 – 7.16 (m, 2H), 7.10 (d, J = 8.1 Hz, 2H), 4.22 (dd, J = 9.6, 3.4 Hz, 1H), 3.67 (s, 3H), 2.87 – 2.80 (m, 1H), 2.68 – 2.61 (m, 1H), 2.35 (d, J = 7.0 Hz, 1H), 2.28 – 2.22 (m, 2H), 2.19 – 2.14 (m, 1H), 1.97 – 1.90 (m, 1H), 1.81 – 1.73 (m, 1H) ppm.

$^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 170.7, 140.4, 137.1, 131.6, 129.9 (2C), 128.5 (2C), 128.4 (2C), 128.3, 126.1 (2C), 86.5, 79.2, 52.6, 51.9, 50.0, 42.0, 34.6, 31.5 ppm.

HRMS (ESI) calculate: $\text{C}_{21}\text{H}_{22}\text{ClO}_3^+$ ($\text{M}+\text{H}$) $^+$: 357.1252, found: 357.1250.

Methyl-3-(4-methylphenethyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



6 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a pale-yellow oil. (20 mg, 0.060 mmol, 60%).


R_f = 0.6 (10% EtOAc in PE).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.45 – 7.29 (m, 5H), 7.17 – 7.08 (m, 4H), 4.33 (dd, J = 9.5, 3.6 Hz, 1H), 3.74 (s, 3H), 2.95 – 2.85 (m, 1H), 2.74 – 2.63 (m, 1H), 2.42 (d, J = 6.9 Hz, 1H), 2.37 – 2.29 (m, 5H), 2.25 (dd, J = 10.1, 7.6 Hz, 1H), 2.07 – 1.96 (m, 1H), 1.92 – 1.80 (m, 1H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 170.9, 138.9, 137.2, 135.3, 129.1 (2C), 128.4 (4C), 128.3, 126.1 (2C), 86.4, 79.6, 52.6, 51.9, 50.0, 41.9, 35.0, 31.8, 21.1 ppm.

HRMS (ESI) calculate: C₂₂H₂₅O₃⁺ (M+H)⁺: 337.1798, found: 337.1795.

Methyl-3-(4-(*tert*-butyl)phenethyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



7 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil (29 mg, 0.076 mmol, 76%).


R_f = 0.6 (10% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.45 – 7.31 (m, 7H), 7.22 – 7.16 (m, 2H), 4.36 (dd, J = 9.5, 3.6 Hz, 1H), 3.75 (s, 3H), 2.97 – 2.88 (m, 1H), 2.75 – 2.66 (m, 1H), 2.43 (d, J = 7.0 Hz, 1H), 2.39 – 2.30 (m, 2H), 2.26 (dd, J = 10.1, 7.7 Hz, 1H), 2.09 – 1.99 (m, 1H), 1.93 – 1.82 (m, 1H), 1.32 (s, 9H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 170.9, 148.7, 138.9, 137.2, 128.4 (2C), 128.3, 128.2 (2C), 126.1 (2C), 125.3 (2C), 86.4, 79.8, 52.7, 52.0, 50.0, 41.9, 34.9, 34.4, 31.7, 31.5 (3C) ppm.

HRMS (ESI) calculate: C₂₅H₃₁O₃⁺ (M+H)⁺: 379.2268, found: 379.2260.

Methyl-3-(4-methoxyphenethyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



8 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (25 mg, 0.070 mmol, 70%).

R_f = 0.4 (10% EtOAc in PE).


¹H NMR (500 MHz, CDCl₃) δ 7.46 – 7.29 (m, 5H), 7.17 (d, J = 8.1 Hz, 2H), 6.85 (d, J = 8.4 Hz, 2H), 4.33 (dd, J = 9.5, 3.5 Hz, 1H), 3.80 (s, 3H), 3.75 (s, 3H), 2.93 – 2.85 (m,

1H), 2.73 – 2.64 (m, 1H), 2.42 (d, $J = 7.0$ Hz, 1H), 2.34 (dd, $J = 14.7, 8.5$ Hz, 2H), 2.26 (dd, $J = 10.2, 7.6$ Hz, 1H), 2.06 – 1.96 (m, 1H), 1.91 – 1.81 (m, 1H) ppm.

^{13}C NMR (151 MHz, CDCl_3) δ 169.8, 156.8, 136.2, 133.0, 128.3 (2C), 127.3 (2C), 127.2, 125.1 (2C), 112.8 (2C), 85.3, 78.5, 54.2, 51.5, 50.8, 48.9, 40.9, 34.0, 30.2 ppm.

HRMS (ESI) calculate: $\text{C}_{22}\text{H}_{25}\text{O}_4^+$ (M+H) $^+$: 353.1747, found: 353.1744.

Methyl-3-ethyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



9 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (25 mg, 0.098 mmol, 98%).


$R_f = 0.6$ (10% EtOAc in PE).

^1H NMR (400 MHz, CDCl_3) δ 7.43 – 7.28 (m, 5H), 4.22 (dd, $J = 8.8, 4.4$ Hz, 1H), 3.75 (s, 3H), 2.42 – 2.17 (m, 4H), 1.79 – 1.67 (m, 1H), 1.63 – 1.54 (m, 1H), 1.05 (t, $J = 7.5$ Hz, 3H) ppm.

^{13}C NMR (126 MHz, CDCl_3) δ 171.1, 137.3, 128.4 (2C), 128.2, 126.1 (2C), 86.2, 81.9, 52.5, 51.9, 50.1, 41.6, 26.0, 10.5 ppm.

HRMS (ESI) calculate: $\text{C}_{15}\text{H}_{19}\text{O}_3^+$ (M+H) $^+$: 261.1485, found: 261.1484.

Methyl-3-benzyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



10 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (16 mg, 0.051 mmol, 51%).


$R_f = 0.6$ (10% EtOAc in PE).

^1H NMR (400 MHz, CDCl_3) δ 7.40 – 7.31 (m, 4H), 7.31 – 7.21 (m, 5H), 7.21 – 7.15 (m, 1H), 4.57 – 4.51 (m, 1H), 3.50 (s, 3H), 3.02 (dd, $J = 14.1, 7.4$ Hz, 1H), 2.93 (dd, $J = 14.0, 5.8$ Hz, 1H), 2.38 (d, $J = 5.8$ Hz, 1H), 2.34 – 2.26 (m, 3H) ppm.

^{13}C NMR (126 MHz, CDCl_3) δ 170.7, 137.8, 137.1, 129.5 (2C), 128.4 (4C), 128.3, 126.4, 126.1 (2C), 86.6, 80.8, 52.6, 51.7, 50.0, 41.6, 39.5 ppm.

HRMS (ESI) calculate: C₂₀H₂₁O₃⁺ (M+H)⁺: 309.1485, found: 309.1483.

Methyl-3-cyclopropyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



11 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (22 mg, 0.086 mmol, 86%).


R_f = 0.6 (10% EtOAc in PE).

¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.26 (m, 5H), 4.28 (d, *J* = 8.9 Hz, 1H), 3.72 (s, 3H), 2.62 – 2.50 (m, 1H), 2.41 – 2.32 (m, 2H), 2.24 – 2.19 (m, 2H), 2.17 – 2.02 (m, 2H), 1.98 – 1.75 (m, 4H) ppm.

¹³C NMR (101 MHz, CDCl₃) δ 171.2, 137.0, 128.5, 128.4, 126.3, 86.3, 86.0, 53.3, 51.9, 49.8, 41.7, 12.5, 3.1, 2.1 ppm.

HRMS (ESI) calculate: C₁₆H₁₉O₃⁺ (M+H)⁺: 259.1329, found: 259.1326.

Methyl-3-cyclobutyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



12 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (21 mg, 0.077 mmol, 77%).

R_f = 0.6 (10% EtOAc in PE).

¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.26 (m, 5H), 4.28 (d, *J* = 8.9 Hz, 1H), 3.72 (s, 3H), 2.62 – 2.50 (m, 1H), 2.41 – 2.32 (m, 2H), 2.24 – 2.19 (m, 2H), 2.17 – 2.02 (m, 2H), 1.98 – 1.75 (m, 4H) ppm.

¹³C NMR (101 MHz, CDCl₃) δ 171.3, 137.1, 128.4 (2C), 128.2, 126.2 (2C), 86.0, 84.7, 52.0, 51.8, 49.8, 41.4, 37.9, 25.8, 24.8, 19.1 ppm.

HRMS (ESI) calculate: C₁₇H₂₁O₃⁺ (M+H)⁺: 273.1485, found: 273.1481.

Methyl-3-cyclopentyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



13 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (25 mg, 0.087 mmol, 87%).


$R_f = 0.6$ (10% EtOAc in PE).

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.41 – 7.28 (m, 5H), 4.07 (d, $J = 9.4$ Hz, 1H), 3.74 (s, 3H), 2.41 – 2.34 (m, 2H), 2.30 – 2.20 (m, 2H), 2.04 – 1.95 (m, 2H), 1.61 – 1.45 (m, 5H), 1.36 – 1.28 (m, 1H), 1.19 – 1.07 (m, 1H) ppm.

$^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 171.7, 137.2, 128.3 (2C), 128.2, 126.1 (2C), 85.7, 85.5, 52.5, 51.8, 50.1, 43.5, 41.4, 30.6, 28.3, 25.6, 25.0 ppm.

HRMS (ESI) calculate: $\text{C}_{18}\text{H}_{23}\text{O}_3^+$ (M+H) $^+$: 287.1642, found: 287.1642.

Methyl-3-cyclohexyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



14 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (25 mg, 0.083 mmol, 83%).


$R_f = 0.6$ (10% EtOAc in PE).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.42 – 7.27 (m, 5H), 4.00 (d, $J = 9.1$ Hz, 1H), 3.74 (s, 3H), 2.35 (d, $J = 3.7$ Hz, 2H), 2.23 (d, $J = 5.1$ Hz, 2H), 2.12 (d, $J = 13.0$ Hz, 1H), 1.82 – 1.70 (m, 2H), 1.61 – 1.52 (m, 1H), 1.52 – 1.44 (m, 1H), 1.32 – 1.13 (m, 4H), 1.12 – 0.94 (m, 2H) ppm.

$^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 172.0, 137.3, 128.4 (2C), 128.1, 126.1 (2C), 85.4, 84.8, 51.9, 51.8, 51.8, 50.9, 41.6, 41.0, 29.8, 28.6, 26.3, 25.8, 25.8 ppm.

HRMS (ESI) calculate: $\text{C}_{19}\text{H}_{25}\text{O}_3^+$ (M+H) $^+$: 301.1798, found: 301.1795.

Methyl-1-phenyl-3-(tetrahydro-2H-pyran-4-yl)-2-oxabicyclo[2.1.1]hexane-4-carboxylate



15 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 5% EtOAc in PE to afford the title compound as a colourless oil (19 mg, 0.063 mmol, 63%).


$R_f = 0.4$ (10% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.40 – 7.34 (m, 4H), 7.33 – 7.29 (m, 1H), 4.04 (d, $J = 9.2$ Hz, 1H), 4.02 – 3.98 (m, 1H), 3.96 – 3.91 (m, 1H), 3.74 (s, 3H), 3.44 – 3.33 (m, 2H), 2.39 – 2.35 (m, 2H), 2.29 (d, $J = 7.8$ Hz, 1H), 2.26 – 2.20 (m, 1H), 2.00 – 1.94 (m, 1H), 1.85 – 1.77 (m, 1H), 1.54 – 1.33 (m, 3H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 171.8, 137.1, 128.5 (2C), 128.4, 126.2 (2C), 85.9, 84.0, 67.9, 67.3, 52.0, 51.9, 51.0, 41.2, 39.1, 29.8, 28.8 ppm.

HRMS (ESI) calculate: $\text{C}_{16}\text{H}_{23}\text{O}_4^+$ ($\text{M}+\text{H}$) $^+$: 303.1591, found: 303.1593.

Methyl-1-phenyl-3-(1-phenylethyl)-2-oxabicyclo[2.1.1]hexane-4-carboxylate



16 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 3% EtOAc in PE to afford the title compound as a colourless oil (18 mg, 0.056 mmol, 56%).


$R_f = 0.6$ (10% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.43 (m, 2H), 7.41 – 7.36 (m, 2H), 7.36 – 7.32 (m, 1H), 7.30 (m, 4H), 7.24 – 7.19 (m, 3H), 4.44 (dd, $J = 9.1, 5.2$ Hz, 1H), 3.01 (s, 3H), 2.93 – 2.86 (m, 1H), 2.38 – 2.35 (m, 2H), 2.32 – 2.30 (m, 1H), 2.28 – 2.25 (m, 1H), 1.47 (d, $J = 6.9$ Hz, 3H), 1.30 (d, $J = 7.1$ Hz, 1H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 170.8, 142.6, 137.2, 128.5 (2C), 128.4 (4C), 128.3, 127.0, 126.2 (2C), 85.8, 84.6, 52.4, 51.2, 50.8, 44.3, 41.0, 19.7 ppm.

HRMS (ESI) calculate: $\text{C}_{21}\text{H}_{23}\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$: 323.1642, found: 323.1642.

Methyl-3-isopropyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



17 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 3% EtOAc in PE to afford the title compound as a colourless oil (20 mg, 0.077 mmol, 77%).


R_f = 0.7 (10% EtOAc in PE)

¹H NMR (500 MHz, CDCl₃) δ 7.41 – 7.33 (m, 4H), 7.33 – 7.28 (m, 1H), 3.93 (d, J = 9.4 Hz, 1H), 3.74 (s, 3H), 2.40 – 2.35 (m, 2H), 2.25 – 2.18 (m, 2H), 1.87 – 1.78 (m, 1H), 1.10 (d, J = 6.6 Hz, 3H), 0.85 (d, J = 6.7 Hz, 3H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 172.1, 137.4, 128.5 (2C), 128.3, 126.2 (2C), 86.2, 85.5, 52.2, 51.9, 51.0, 41.3, 32.1, 20.0, 18.7 ppm.

HRMS (ESI) calculate: C₁₆H₂₁O₃⁺ (M+H)⁺: 261.1485, found: 261.1487.

Methyl-3-(3-((*tert*-butyldiphenylsilyl)oxy)propyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



18 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a colourless oil (32 mg, 0.062 mmol, 62%).


R_f = 0.8 (10% EtOAc in PE)

¹H NMR (500 MHz, CDCl₃) δ 7.72 – 7.68 (m, 4H), 7.45 – 7.37 (m, 10H), 7.36 – 7.31 (m, 1H), 4.32 (dd, J = 9.3, 3.2 Hz, 1H), 3.81 – 3.71 (m, 5H), 2.43 (d, J = 6.9 Hz, 1H), 2.35 (dd, J = 10.1, 7.0 Hz, 1H), 2.31 (d, J = 7.6 Hz, 1H), 2.23 (dd, J = 10.2, 7.6 Hz, 1H), 1.93 – 1.83 (m, 2H), 1.75 – 1.61 (m, 2H), 1.08 (s, 9H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 171.0, 137.4, 135.7 (3C), 134.2, 134.1, 129.7 (2C), 128.4 (2C), 128.3 (2C), 127.7 (4C), 126.2 (2C), 86.4, 80.3, 63.8, 52.8, 51.9, 50.0, 41.9, 29.3, 29.1, 23.0 (3C), 19.4 ppm.

HRMS (ESI) calculate: C₃₂H₃₉O₄Si⁺ (M+H)⁺: 515.2539, found: 515.2542.

Methyl-3-(5-ethoxy-5-oxopentyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



19 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 4% EtOAc in PE to afford the title compound as a colourless oil (22 mg, 0.064 mmol, 64%).


R_f = 0.5 (10% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.41 – 7.33 (m, 4H), 7.33 – 7.28 (m, 1H), 4.27 (dd, J = 9.1, 3.6 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.76 (s, 3H), 2.40 (d, J = 7.0 Hz, 1H), 2.35 – 2.27 (m, 4H), 2.21 (dd, J = 10.2, 7.7 Hz, 1H), 1.75 – 1.67 (m, 3H), 1.65 – 1.53 (m, 2H), 1.48 – 1.40 (m, 1H), 1.27 – 1.23 (m, 3H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 173.8, 171.0, 137.3, 128.5 (2C), 128.3, 126.2 (2C), 86.5, 80.2, 60.4, 52.7, 52.0, 50.0, 41.9, 34.4, 32.7, 25.8, 25.2, 14.4 ppm.

HRMS (ESI) calculate: $\text{C}_{20}\text{H}_{28}\text{O}_5^+$ ($\text{M}+\text{H}$) $^+$: 347.1853, found: 347.1852.

Methyl-3-isobutyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



20 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a colourless oil (20 mg, 0.073 mmol, 73%).


R_f = 0.8 (10% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.45 – 7.33 (m, 4H), 7.30 (app. t, J = 7.2 Hz, 1H), 4.38 (dd, J = 9.0, 3.9 Hz, 1H), 3.76 (s, 3H), 2.40 (d, J = 6.9 Hz, 1H), 2.36 – 2.30 (m, 1H), 2.27 (d, J = 7.5 Hz, 1H), 2.25 – 2.19 (m, 1H), 1.91 – 1.79 (m, 1H), 1.56 – 1.43 (m, 2H), 0.99 (dd, J = 6.7, 4.2 Hz, 6H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 171.2, 137.4, 128.5 (2C), 128.3, 126.2 (2C), 86.4, 78.7, 52.8, 52.0, 49.9, 42.0, 41.9, 25.3, 23.7, 22.4 ppm.

HRMS (ESI) calculate: $\text{C}_{17}\text{H}_{23}\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$: 275.1642, found: 275.1642.

Methyl-3-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



21 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a colourless oil (20 mg, 0.053 mmol, 53%).


R_f = 0.6 (10% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.42 – 7.34 (m, 4H), 7.33 – 7.29 (m, 1H), 4.42 (dd, J = 9.7, 3.2 Hz, 1H), 3.88 – 3.79 (m, 2H), 3.76 (s, 3H), 2.41 (d, J = 6.9 Hz, 1H), 2.32 (dd, J = 8.8, 5.4 Hz, 2H), 2.21 (dd, J = 10.3, 7.8 Hz, 1H), 2.02 – 1.93 (m, 1H), 1.81 – 1.73 (m, 1H), 0.91 (s, 9H), 0.08 (d, J = 1.7 Hz, 6H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 170.8, 137.4, 128.4 (2C), 128.3, 126.2 (2C), 86.6, 76.9, 60.2, 52.7, 52.0, 50.1, 42.0, 36.4, 26.1 (3C), 18.5, 5.1 (2C) ppm.

HRMS (ESI) calculate: $\text{C}_{21}\text{H}_{33}\text{O}_4\text{Si}^+$ ($\text{M}+\text{H}$) $^+$: 377.2143, found: 377.2139.

Methyl-(4-chlorobutyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



22 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 4% EtOAc in PE to afford the title compound as a colourless oil (20 mg, 0.065 mmol, 65%).


R_f = 0.4 (10% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.41 – 7.34 (m, 4H), 7.34 – 7.29 (m, 1H), 4.31 – 4.25 (m, 1H), 3.76 (s, 3H), 3.56 (t, J = 6.7 Hz, 2H), 2.41 (d, J = 7.0 Hz, 1H), 2.35 – 2.29 (m, 2H), 2.21 (dd, J = 10.2, 7.7 Hz, 1H), 1.89 – 1.83 (m, 2H), 1.78 – 1.69 (m, 2H), 1.62 – 1.54 (m, 2H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 171.0, 137.3, 128.5 (2C), 128.4, 126.2 (2C), 86.5, 80.1, 52.7, 52.0, 50.1, 45.0, 41.9, 32.7, 32.3, 23.7 ppm.

HRMS (ESI) calculate: $\text{C}_{17}\text{H}_{22}\text{ClO}_3^+$ ($\text{M}+\text{H}$) $^+$: 395.1252, found: 395.1250.

Methyl-hexyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



23 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a colourless oil (17 mg, 0.056 mmol, 56%).


R_f = 0.8 (10% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.41 – 7.38 (m, 2H), 7.38 – 7.33 (m, 2H), 7.33 – 7.28 (m, 1H), 4.28 (dd, J = 8.7, 4.1 Hz, 1H), 3.75 (s, 3H), 2.39 (d, J = 6.9 Hz, 1H), 2.33 (dd, J = 10.0, 7.0 Hz, 1H), 2.28 (d, J = 7.5 Hz, 1H), 2.22 (dd, J = 10.0, 7.6 Hz, 1H), 1.72 – 1.64 (m, 1H), 1.57 (m, 2H), 1.41 – 1.33 (m, 3H), 1.32 – 1.25 (m, 4H), 0.88 (t, J = 6.7 Hz, 3H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 171.2, 137.4, 128.5 (2C), 128.3, 126.2 (2C), 86.3, 80.6, 52.7, 52.0, 50.1, 41.8, 33.1, 31.9, 29.6, 26.2, 22.8, 14.2 ppm.

HRMS (ESI) calculate: $\text{C}_{19}\text{H}_{28}\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$: 303.1955, found: 303.1953.

Methyl-3-(3-((4,4-difluorocyclohexane-1-carbonyl)oxy)propyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



24 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 8% EtOAc in PE to afford the title compound as a colourless oil (28 mg, 0.066 mmol, 66%).

R_f = 0.3 (10% EtOAc in PE)


$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.41 – 7.34 (m, 4H), 7.34 – 7.29 (m, 1H), 4.29 (dd, J = 9.7, 2.9 Hz, 1H), 4.24 – 4.10 (m, 2H), 3.76 (s, 3H), 2.42 (d, J = 7.4 Hz, 2H), 2.37 – 2.30 (m, 2H), 2.24 – 2.16 (m, 1H), 2.14 – 2.02 (m, 2H), 2.02 – 1.90 (m, 3H), 1.86 – 1.73 (m, 5H), 1.63 – 1.55 (m, 2H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 174.4, 170.8, 137.1, 128.5 (2C), 128.4, 126.2 (2C), 122.8 (t, J = 240.3 Hz), 86.7, 79.7, 64.6, 52.7, 52.1, 50.1, 41.9, 40.7, 32.7 (t, J = 24.4 Hz, 2C), 29.4, 25.5, 25.2 (d, J = 7.9 Hz, 2C) ppm.

^{19}F NMR (376 MHz, CDCl_3) δ -94.29 (d, J = 237.3 Hz), -99.56 (d, J = 237.9 Hz) ppm.

HRMS (ESI) calculate: $\text{C}_{23}\text{H}_{29}\text{F}_2\text{O}_6^+$ ($\text{M}+\text{H}$) $^+$: 423.1978, found: 423.1979.

Methyl-3-(3-(2-(2,4-dichlorophenoxy)acetoxy)propyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



25 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 10% EtOAc in PE to afford the title compound as a colourless oil (25 mg, 0.052 mmol, 52%).


R_f = 0.2 (10% EtOAc in PE)

^1H NMR (500 MHz, CDCl_3) δ 7.37 (d, J = 6.7 Hz, 5H), 7.34 – 7.29 (m, 1H), 7.16 – 7.11 (m, 1H), 6.77 (dd, J = 8.8, 2.1 Hz, 1H), 4.68 (d, J = 2.2 Hz, 2H), 4.34 – 4.22 (m, 3H), 3.76 (d, J = 2.1 Hz, 3H), 2.42 (dd, J = 7.2, 2.0 Hz, 1H), 2.35 – 2.28 (m, 2H), 2.17 (t, J = 9.2 Hz, 1H), 2.02 – 1.91 (m, 1H), 1.84 – 1.75 (m, 2H), 1.63 – 1.51 (m, 1H) ppm.

^{13}C NMR (126 MHz, CDCl_3) δ 170.7, 168.3, 152.5, 137.1, 130.4, 128.5 (2C), 128.4, 127.7, 127.1, 126.1 (2C), 124.3, 114.8, 86.7, 79.6, 66.5, 65.6, 52.7, 52.1, 50.0, 42.0, 29.3, 25.4 ppm.

HRMS (ESI) calculate: $\text{C}_{24}\text{H}_{25}\text{Cl}_2\text{O}_6^+$ ($\text{M}+\text{H}$) $^+$: 479.1023, found: 479.1026.

Methyl-3-(3-((4-([1,1'-biphenyl]-4-yl)-4-oxobutanoyl)oxy)propyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



26 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 12% EtOAc in PE to afford the title compound as a colourless oil (31 mg, 0.060 mmol, 60%).

R_f = 0.3 (20% EtOAc in PE)

^1H NMR (500 MHz, CDCl_3) δ 8.06 (d, J = 8.2 Hz, 2H), 7.68 (d, J = 8.1 Hz, 2H), 7.63 (d, J = 7.3 Hz, 2H), 7.47 (app. t, J = 7.5 Hz, 2H), 7.43 – 7.34 (m, 5H), 7.33 – 7.29 (m,

1H), 4.30 (dd, $J = 9.5, 3.3$ Hz, 1H), 4.25 – 4.15 (m, 2H), 3.77 (s, 3H), 3.35 (t, $J = 6.7$ Hz, 2H), 2.80 (t, $J = 6.7$ Hz, 2H), 2.42 (d, $J = 7.0$ Hz, 1H), 2.36 – 2.28 (m, 2H), 2.21 (dd, $J = 10.3, 7.7$ Hz, 1H), 1.97 (d, $J = 5.9$ Hz, 1H), 1.87 – 1.74 (m, 2H), 1.67 – 1.57 (m, 1H) ppm.

^{13}C NMR (126 MHz, CDCl_3) δ 197.8, 173.1, 170.8, 145.9, 140.0, 137.2, 135.4, 129.1 (2C), 128.8 (2C), 128.4 (2C), 128.3, 128.3, 127.4 (4C), 126.2 (2C), 86.6, 79.8, 64.7, 52.7, 52.1, 50.0, 41.9, 33.5, 29.5, 28.4, 25.4 ppm.

HRMS (ESI) calculate: $\text{C}_{32}\text{H}_{33}\text{O}_6$ (M+H) $^+$: 513.2272, found: 513.2269.

Methyl-3-(3-((2-(3-fluoro-[1,1'-biphenyl]-4-yl)propanoyl)oxy)propyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



27 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 8% EtOAc in PE to afford the title compound as a colourless oil (30 mg, 0.060 mmol, 60%).

$R_f = 0.3$ (10% EtOAc in PE)


^1H NMR (500 MHz, CDCl_3) δ 7.52 (d, $J = 7.6$ Hz, 2H), 7.43 (app. t, $J = 7.8$ Hz, 2H), 7.40 – 7.33 (m, 6H), 7.31 (d, $J = 6.1$ Hz, 1H), 7.14 (app. t, $J = 11.2$ Hz, 2H), 4.27 (d, $J = 9.4$ Hz, 1H), 4.22 – 4.16 (m, 2H), 3.79 – 3.74 (m, 1H), 3.72 (d, $J = 2.5$ Hz, 3H), 2.41 (d, $J = 7.2$ Hz, 1H), 2.33 – 2.26 (m, 2H), 2.14 (s, 1H), 1.99 – 1.89 (m, 1H), 1.76 (d, $J = 3.5$ Hz, 2H), 1.55 (s, 2H), 1.53 (d, $J = 2.5$ Hz, 2H) ppm.

^{13}C NMR (126 MHz, CDCl_3) δ 174.1, 170.8, 159.8 (d, $J = 248.1$ Hz), 142.0 (d, $J = 7.8$ Hz), 137.2, 135.6, 130.9 (d, $J = 3.8$ Hz), 129.1 (d, $J = 2.9$ Hz, 2C), 128.5 (2C), 128.5 (2C), 128.4, 127.9, 127.7, 126.1 (2C), 123.7, 115.4 (d, $J = 23.7$ Hz), 86.6, 79.8, 52.7, 52.0, 50.0, 45.2, 41.9, 41.9, 29.3, 25.4, 18.5 ppm.

^{19}F NMR (471 MHz, CDCl_3) δ -117.65 ppm.

HRMS (ESI) calculate: $\text{C}_{31}\text{H}_{32}\text{FO}_5$ (M+H) $^+$: 503.2228, found: 503.2230.

Methyl-3-(3-((2-(3-acetoxybenzoyl)oxy)propyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



28 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 10% EtOAc in PE to afford the title compound as a colourless oil (33 mg, 0.075 mmol, 75%).


$R_f = 0.4$ (20% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.03 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.58 – 7.53 (m, 1H), 7.42 – 7.34 (m, 4H), 7.34 – 7.28 (m, 2H), 7.10 (dd, $J = 8.1, 1.2$ Hz, 1H), 4.40 – 4.31 (m, 3H), 3.75 (s, 3H), 2.43 (d, $J = 7.0$ Hz, 1H), 2.33 (d, $J = 10.2$ Hz, 5H), 2.24 (dd, $J = 10.3, 7.7$ Hz, 1H), 2.12 – 2.03 (m, 1H), 1.94 – 1.84 (m, 2H), 1.72 – 1.63 (m, 1H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 170.8, 169.8, 164.6, 150.7, 137.1, 133.9, 131.9, 128.4 (2C), 128.3, 126.1 (2C), 126.1, 123.9, 123.5, 86.7, 79.7, 65.2, 52.7, 52.0, 50.1, 41.9, 29.5, 25.5, 21.2 ppm.

HRMS (ESI) calculate: $\text{C}_{25}\text{H}_{27}\text{O}_7^+$ ($\text{M}+\text{H}$) $^+$: 439.1751, found: 439.1754.

Methyl-3-(3-((2-(4-benzoylphenyl)propanoyl)oxy)propyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



29 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 15% EtOAc in PE to afford the title compound as a colourless oil (29 mg, 0.057 mmol, 57%).


$R_f = 0.3$ (20% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.79 (d, $J = 7.6$ Hz, 2H), 7.75 (d, $J = 2.5$ Hz, 1H), 7.69 – 7.64 (m, 1H), 7.60 – 7.52 (m, 2H), 7.50 – 7.45 (m, 2H), 7.42 (d, $J = 7.4$ Hz, 1H), 7.39 – 7.32 (m, 4H), 7.32 – 7.27 (m, 1H), 4.28 – 4.22 (m, 1H), 4.21 – 4.11 (m, 2H), 3.84 – 3.76 (m, 1H), 3.72 (d, $J = 2.3$ Hz, 3H), 2.40 (dd, $J = 7.1, 2.3$ Hz, 1H), 2.29 (t, $J = 10.0$ Hz, 2H), 2.13 (t, $J = 9.1$ Hz, 1H), 1.95 – 1.86 (m, 1H), 1.78 – 1.70 (m, 2H), 1.54 (d, $J = 2.3$ Hz, 2H), 1.52 (d, $J = 2.3$ Hz, 2H) ppm.

^{13}C NMR (126 MHz, CDCl_3) δ 196.6, 174.2, 170.8, 141.0, 138.0, 137.6, 137.1, 132.6, 131.7, 130.2 (2C), 129.4, 129.1, 128.7, 128.5 (2C), 128.4 (2C), 128.3, 126.1 (2C), 86.6, 79.7, 65.0, 52.7, 52.0, 50.0, 45.6, 41.9, 29.3, 25.4, 18.6 ppm.

HRMS (ESI) calculate: $\text{C}_{32}\text{H}_{33}\text{O}_6^+$ (M+H) $^+$: 513.2272, found: 513.2274.

Methyl-3-(3-(((S)-2-(4-isobutylphenyl)propanoyl)oxy)propyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



30 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 5% EtOAc in PE to afford the title compound as a colourless oil (31 mg, 0.067 mmol, 67%).


R_f = 0.5 (10% EtOAc in PE)

^1H NMR (500 MHz, CDCl_3) δ 7.40 – 7.34 (m, 4H), 7.34 – 7.29 (m, 1H), 7.20 (d, J = 7.7 Hz, 2H), 7.07 (dd, J = 7.5, 5.0 Hz, 2H), 4.25 (dd, J = 9.4, 3.0 Hz, 1H), 4.19 – 4.10 (m, 2H), 3.75 – 3.72 (m, 3H), 3.72 – 3.66 (m, 1H), 2.45 – 2.38 (m, 3H), 2.30 (dd, J = 15.7, 8.3 Hz, 2H), 2.17 – 2.10 (m, 1H), 1.94 – 1.86 (m, 1H), 1.86 – 1.78 (m, 1H), 1.77 – 1.67 (m, 2H), 1.57 – 1.46 (m, 4H), 0.90 (d, J = 2.4 Hz, 3H), 0.88 (s, 3H) ppm.

^{13}C NMR (126 MHz, CDCl_3) δ 174.9, 170.8, 140.6, 137.9, 137.2, 129.4 (2C), 128.5 (2C), 128.3, 127.3 (2C), 126.1 (2C), 86.6, 79.8, 64.7, 52.7, 52.0, 50.0, 45.3, 45.2, 41.9, 30.3, 29.3, 25.4, 22.5 (2C), 18.7 ppm.

HRMS (ESI) calculate: $\text{C}_{29}\text{H}_{38}\text{O}_5^+$ (M+H) $^+$: 465.2636, found: 465.2637.

Methyl-(3-(2-(11-oxo-6,11-dihydrodibenzo[*b,e*]oxepin-2-yl)acetoxyl)propyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



31 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 15% EtOAc in PE to afford the title compound as a colourless oil (28 mg, 0.053 mmol, 53%).


$R_f = 0.5$ (30% EtOAc in PE)

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.11 (d, $J = 2.3$ Hz, 1H), 7.88 (dd, $J = 7.7, 1.4$ Hz, 1H), 7.60 – 7.52 (m, 1H), 7.50 – 7.40 (m, 2H), 7.40 – 7.27 (m, 6H), 7.02 (d, $J = 8.5$ Hz, 1H), 5.17 (s, 2H), 4.28 (dd, $J = 9.6, 3.1$ Hz, 1H), 4.25 – 4.13 (m, 2H), 3.75 (s, 3H), 3.64 (s, 2H), 2.41 (d, $J = 7.0$ Hz, 1H), 2.35 – 2.25 (m, 2H), 2.18 (dd, $J = 10.2, 7.7$ Hz, 1H), 2.01 – 1.89 (m, 1H), 1.84 – 1.72 (m, 2H), 1.63 – 1.51 (m, 1H) ppm.

$^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 191.0, 171.6, 170.8, 160.6, 140.6, 137.2, 136.5, 135.7, 132.9, 132.6, 129.6, 129.4, 128.5 (2C), 128.4, 128.0, 127.9, 126.2 (2C), 125.2, 121.2, 86.6, 79.8, 73.7, 65.0, 52.7, 52.1, 50.0, 42.0, 40.4, 29.4, 25.4 ppm.

HRMS (ESI) calculate: $\text{C}_{32}\text{H}_{30}\text{O}_7^+$ ($\text{M}+\text{H}$) $^+$: 527.2064, found: 527.2066.

Methyl-1-phenyl-3-(3-((2-propylpentanoyl)oxy)propyl)-2-oxabicyclo[2.1.1]hexane-4-carboxylate



32 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 3% EtOAc in PE to afford the title compound as a colourless oil (29 mg, 0.072 mmol, 72%).


$R_f = 0.4$ (10% EtOAc in PE)

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.42 – 7.34 (m, 4H), 7.34 – 7.28 (m, 1H), 4.30 (dd, $J = 9.6, 3.3$ Hz, 1H), 4.15 (t, $J = 6.4$ Hz, 2H), 3.76 (s, 3H), 2.42 (d, $J = 7.0$ Hz, 1H), 2.40 – 2.28 (m, 3H), 2.21 (dd, $J = 10.2, 7.7$ Hz, 1H), 1.99 – 1.90 (m, 1H), 1.85 – 1.70 (m, 2H), 1.64 – 1.52 (m, 3H), 1.46 – 1.34 (m, 2H), 1.32 – 1.25 (m, 4H), 0.94 – 0.85 (m, 6H) ppm.

$^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 176.8, 170.8, 137.2, 128.5 (2C), 128.4, 126.2 (2C), 86.6, 79.9, 64.0, 52.7, 52.0, 50.0, 45.5, 41.9, 34.8 (2C), 29.5, 25.6, 20.8 (2C), 14.2 (2C) ppm.

HRMS (ESI) calculate: $\text{C}_{24}\text{H}_{35}\text{O}_6^+$ ($\text{M}+\text{H}$) $^+$: 403.2479, found: 403.2480.

Methyl-1,3-diphenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



33 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a pale-yellow solid. (25 mg, 0.085 mmol, 85%).


$R_f = 0.6$ (10% EtOAc in PE)

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.55 – 7.49 (m, 2H), 7.48 – 7.39 (m, 4H), 7.39 – 7.32 (m, 3H), 7.32 – 7.27 (m, 1H), 5.51 (s, 1H), 3.74 (s, 3H), 2.64 – 2.58 (m, 1H), 2.55 (d, $J = 7.0$ Hz, 1H), 2.31 (dd, $J = 10.0, 8.0$ Hz, 1H), 2.23 (d, $J = 8.1$ Hz, 1H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 170.6, 139.6, 137.1, 128.6 (2C), 128.5, 128.2 (2C), 127.8, 126.6 (2C), 126.3 (2C), 86.9, 80.4, 54.7, 52.0, 51.0, 39.9 ppm.

HRMS (ESI) calculate: $\text{C}_{19}\text{H}_{19}\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$: 295.1329, found: 295.1330.

Methyl-1-phenyl-3-(p-tolyl)-2-oxabicyclo[2.1.1]hexane-4-carboxylate



34 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a pale-yellow solid. (23 mg, 0.076 mmol, 76%).


$R_f = 0.6$ (10% EtOAc in PE)

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.54 – 7.49 (m, 2H), 7.46 – 7.30 (m, 5H), 7.16 (d, $J = 7.9$ Hz, 2H), 5.49 (s, 1H), 3.74 (s, 3H), 2.63 – 2.51 (m, 2H), 2.35 (s, 3H), 2.31 (dd, $J = 10.1, 8.1$ Hz, 1H), 2.22 (d, $J = 8.0$ Hz, 1H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 170.6, 137.4, 137.1, 136.5, 128.9 (2C), 128.5 (2C), 128.4, 126.4 (2C), 126.2 (2C), 86.8, 80.3, 54.6, 51.8, 50.8, 39.9, 21.2 ppm.

HRMS (ESI) calculate: $\text{C}_{20}\text{H}_{21}\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$: 309.1485, found: 309.1482.

Methyl-3-([1,1'-biphenyl]-4-yl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



35 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a pale-yellow solid. (29 mg, 0.079 mmol, 79%).

R_f = 0.6 (10% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.61 – 7.57 (m, 4H), 7.56 – 7.51 (m, 4H), 7.47 – 7.41 (m, 4H), 7.40 – 7.33 (m, 2H), 5.56 (s, 1H), 3.77 (s, 3H), 2.63 (dd, J = 10.1, 7.1 Hz, 1H), 2.57 (d, J = 7.0 Hz, 1H), 2.35 (dd, J = 10.1, 8.1 Hz, 1H), 2.27 (d, J = 8.1 Hz, 1H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 170.6, 140.9, 140.6, 138.6, 137.0, 128.8 (2C), 128.5 (2C), 128.4, 127.3, 127.2 (2C), 127.0 (2C), 126.9 (2C), 126.2 (2C), 86.9, 80.2, 54.7, 51.9, 51.0, 40.0 ppm.

HRMS (ESI) calculate: $\text{C}_{25}\text{H}_{23}\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$: 371.1642, found: 371.1638.

Methyl-3-(4-fluorophenyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



36 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a pale-yellow solid. (22 mg, 0.059 mmol, 59%).

R_f = 0.6 (10% EtOAc in PE).

$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.52 – 7.48 (m, 2H), 7.45 – 7.39 (m, 4H), 7.39 – 7.34 (m, 1H), 7.04 (t, J = 8.7 Hz, 2H), 5.47 (s, 1H), 3.74 (s, 3H), 2.61 – 2.52 (m, 2H), 2.28 – 2.22 (m, 2H) ppm.

$^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 169.3, 161.4 (d, J = 245.8 Hz), 135.8, 134.2 (d, J = 3.1 Hz), 127.4 (2C), 127.4, 127.2 (d, J = 8.1 Hz, 2C), 125.1 (2C), 114.0 (d, J = 21.7 Hz, 2C), 85.9, 78.7, 53.6, 50.8, 49.9, 38.7 ppm.

$^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -114.88 ppm.

HRMS (ESI) calculate: C₁₉H₁₈FO₃⁺ (M+H)⁺: 313.1234, found: 313.1227.

Methyl-3-(4-chlorophenyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



37 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a pale-yellow solid (18 mg, 0.055 mmol, 55%).

R_f = 0.6 (10% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.49 (d, *J* = 7.5 Hz, 2H), 7.45 – 7.35 (m, 5H), 7.32 (d, *J* = 8.2 Hz, 2H), 5.46 (s, 1H), 3.73 (s, 3H), 2.65 – 2.49 (m, 2H), 2.30 – 2.18 (m, 2H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 170.3, 138.0, 136.7, 133.6, 128.5, 128.3, 128.0, 126.2, 87.1, 79.7, 54.6, 51.9, 51.0, 39.7 ppm.

HRMS (ESI) calculate: C₁₉H₁₈ClO₃⁺ (M+H)⁺: 329.0939, found: 329.0941.

Methyl-3-(4-bromophenyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



38 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a pale yellow solid. (23 mg, 0.061 mmol, 61%).


R_f = 0.6 (10% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.52 – 7.45 (m, 4H), 7.45 – 7.40 (m, 2H), 7.40 – 7.36 (m, 1H), 7.34 (dd, *J* = 8.6, 2.8 Hz, 2H), 5.45 (d, *J* = 2.7 Hz, 1H), 3.74 (s, 3H), 2.62 – 2.52 (m, 2H), 2.26 – 2.19 (m, 2H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 170.3, 138.6, 136.7, 131.3 (2C), 128.5 (3C), 128.3 (2C), 126.2 (2C), 121.8, 87.1, 79.7, 54.6, 52.0, 51.0, 39.7 ppm.

HRMS (ESI) calculate: C₁₉H₁₈BrO₃⁺ (M+H)⁺: 373.0434, found: 373.0428.

Methyl-1-phenyl-3-(4-(trifluoromethoxy)phenyl)-2-oxabicyclo[2.1.1]hexane-4-carboxylate



39 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 5% EtOAc in PE to afford the title compound as a pale-yellow oil. (22 mg, 0.058 mmol, 58%).

R_f = 0.5 (10% EtOAc in PE).


$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.54 – 7.47 (m, 4H), 7.46 – 7.34 (m, 3H), 7.20 (d, J = 8.3 Hz, 2H), 5.50 (s, 1H), 3.75 (s, 3H), 2.64 – 2.54 (m, 2H), 2.30 – 2.20 (m, 2H) ppm.

$^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 169.2, 147.7, 137.1, 135.7, 127.5 (3C), 127.0 (2C), 125.1 (2C), 119.5 (2C), 119.4 (q, J = 256.8 Hz), 86.1, 78.5, 53.6, 50.9, 50.0, 38.7 ppm.

$^{19}\text{F NMR}$ (471 MHz, CDCl_3) δ -57.76 ppm.

HRMS (ESI) calculate: $\text{C}_{20}\text{H}_{18}\text{F}_3\text{O}_4^+$ ($\text{M}+\text{H}$) $^+$: 379.1152, found: 379.1155.

Methyl-3-(4-phenoxyphenyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



40 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (23 mg, 0.0609 mmol, 60%).


R_f = 0.5 (10% EtOAc in PE).

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.53 – 7.48 (m, 2H), 7.45 – 7.38 (m, 4H), 7.38 – 7.31 (m, 3H), 7.14 – 7.08 (m, 1H), 7.04 – 6.96 (m, 4H), 5.49 (s, 1H), 3.75 (s, 3H), 2.62 – 2.52 (m, 2H), 2.34 – 2.22 (m, 2H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 170.5, 157.1, 156.9, 136.9, 134.2, 129.8 (2C), 128.5 (2C), 128.4, 128.0 (2C), 126.2 (2C), 123.4, 119.1 (2C), 118.4 (2C), 86.9, 80.0, 54.6, 51.9, 50.9, 39.9 ppm.

HRMS (ESI) calculate: C₂₅H₂₃O₄⁺ (M+H)⁺: 387.1591, found: 387.1589.

Methyl-3-(4-(tert-butyl)phenyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



41 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow solid. (27 mg, 0.077 mmol, 77%).


R_f = 0.6 (10% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.53 – 7.49 (m, 2H), 7.43 – 7.39 (m, 2H), 7.38 – 7.34 (m, 5H), 5.48 (s, 1H), 3.76 (s, 3H), 2.61 – 2.53 (m, 2H), 2.32 (dd, *J* = 10.0, 8.0 Hz, 1H), 2.23 (d, *J* = 8.1 Hz, 1H), 1.32 (s, 9H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 170.7, 150.5, 137.1, 136.5, 128.4 (2C), 128.3, 126.2 (4C), 125.1 (2C), 86.7, 80.2, 54.5, 51.9, 50.9, 40.1, 34.6, 31.4 (3C) ppm.

HRMS (ESI) calculate: C₂₃H₂₇O₃⁺ (M+H)⁺: 351.1955, found: 351.1948.

Methyl-3-(3-methoxyphenyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



42 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow solid. (19 mg, 0.063s mmol, 63%).


R_f = 0.5 (10% EtOAc in PE).

¹H NMR (600 MHz, CDCl₃) δ 7.53 – 7.48 (m, 2H), 7.43 – 7.35 (m, 5H), 6.89 (d, *J* = 8.4 Hz, 2H), 5.46 (s, 1H), 3.81 (s, 3H), 3.73 (s, 3H), 2.58 (dd, *J* = 10.1, 7.1 Hz, 1H), 2.53 (d, *J* = 7.0 Hz, 1H), 2.30 (dd, *J* = 10.1, 8.0 Hz, 1H), 2.23 (d, *J* = 8.0 Hz, 1H) ppm.

¹³C NMR (151 MHz, CDCl₃) δ 169.5, 158.1, 136.0, 130.5, 127.4 (2C), 127.3, 126.7 (2C), 125.1 (2C), 112.5 (2C), 85.7, 79.1, 54.2, 53.5, 50.8, 49.8, 38.8 ppm.

HRMS (ESI) calculate: C₂₀H₂₁O₄⁺ (M+H)⁺: 325.1434, found: 325.1431.

Methyl-3-(3-methoxyphenyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



43 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (20 mg, 0.061 mmol, 61%).


R_f = 0.5 (10% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.45 – 7.40 (m, 2H), 7.36 – 7.27 (m, 3H), 7.19 – 7.14 (m, 1H), 6.96 – 6.91 (m, 2H), 6.75 (dd, *J* = 8.3, 2.5 Hz, 1H), 5.39 (s, 1H), 3.72 (s, 3H), 3.66 (s, 3H), 2.54 – 2.43 (m, 2H), 2.26 – 2.11 (m, 2H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 170.5, 159.5, 141.2, 137.0, 129.2, 128.5 (2C), 128.4, 126.2 (2C), 118.7, 113.1, 112.3, 86.9, 80.2, 55.2, 54.6, 51.9, 50.9, 40.0 ppm.

HRMS (ESI) calculate: C₂₀H₂₁O₄⁺ (M+H)⁺: 325.1434, found: 325.1431.

Methyl-3-(3,4-dimethoxyphenyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



44 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 10% EtOAc in PE to afford the title compound as a pale-yellow solid. (22 mg, 0.063 mmol, 63%).


R_f = 0.3 (10% EtOAc in PE).

¹H NMR (400 MHz, CDCl₃) δ 7.53 – 7.47 (m, 2H), 7.45 – 7.33 (m, 3H), 7.03 – 6.96 (m, 2H), 6.85 (d, *J* = 8.2 Hz, 1H), 5.46 (s, 1H), 3.87 (d, *J* = 2.6 Hz, 6H), 3.74 (s, 3H), 2.62 – 2.50 (m, 2H), 2.33 – 2.21 (m, 2H) ppm.

¹³C NMR (101 MHz, CDCl₃) δ 170.6, 148.6, 148.5, 137.0, 132.0, 128.5 (2C), 128.4 (2C), 126.2, 118.7, 110.7, 109.7, 86.8, 80.1, 55.9, 55.9, 54.6, 51.9, 50.9, 39.9 ppm.

HRMS (ESI) calculate: C₂₁H₂₃O₅⁺ (M+H)⁺: 355.1540, found: 355.1534.

Methyl-1-phenyl-3-(3,4,5-trimethoxyphenyl)-2-oxabicyclo[2.1.1]hexane-4-carboxylate



45 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 10% EtOAc in PE to afford the title compound as a pale-yellow solid. (26 mg, 0.067 mmol, 67%).

$R_f = 0.2$ (10% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.51 – 7.47 (m, 2H), 7.45 – 7.35 (m, 3H), 6.68 (s, 2H), 5.45 (s, 1H), 3.84 (s, 9H), 3.75 (s, 3H), 2.63 – 2.51 (m, 2H), 2.33 – 2.22 (m, 2H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 170.6, 153.0 (2C), 137.3, 136.9, 135.2, 128.5 (2C), 128.5, 126.2 (2C), 103.4 (2C), 86.9, 80.2, 60.9, 56.1 (2C), 54.7, 51.9, 51.1, 39.9 ppm.

HRMS (ESI) calculate: C₂₂H₂₅O₆⁺ (M+H)⁺: 385.1646, found: 385.1637.

Methyl-3-(2-fluoro-4-methylphenyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



46 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (21 mg, 0.066 mmol, 66%).

$R_f = 0.5$ (10% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.54 – 7.32 (m, 7H), 6.98 (d, *J* = 7.8 Hz, 1H), 6.86 (d, *J* = 11.5 Hz, 1H), 5.60 (s, 1H), 3.73 (s, 3H), 2.62 – 2.49 (m, 2H), 2.38 – 2.31 (m, 4H), 2.19 (d, *J* = 8.1 Hz, 1H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 170.6, 160.1 (d, *J* = 246.7 Hz), 140.0 (d, *J* = 8.27 Hz), 136.7, 128.6, 128.5 (2C), 128.5, 126.3 (2C), 124.6, 123.4 (d, *J* = 13.8 Hz), 115.5 (d, *J* = 21.2 Hz), 86.4, 76.1, 53.7, 51.9, 49.3, 41.1, 21.1 ppm.

¹⁹F NMR (471 MHz, CDCl₃) δ -118.31 ppm.

HRMS (ESI) calculate: C₂₀H₂₀FO₃⁺ (M+H)⁺: 327.1391, found: 327.1386.

Methyl-3-(3-fluoro-4-methylphenyl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



47 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a pale-yellow oil. (23 mg, 0.069 mmol, 69%).

R_f = 0.5 (10% EtOAc in PE).


¹H NMR (500 MHz, CDCl₃) δ 7.55 – 7.32 (m, 6H), 7.24 – 7.17 (m, 1H), 6.97 (app. t, J = 8.9 Hz, 1H), 5.44 (s, 1H), 3.74 (s, 3H), 2.61 – 2.49 (m, 2H), 2.30 – 2.22 (m, 5H) ppm.

¹³C NMR (151 MHz, CDCl₃) δ 170.5, 160.9 (d, J = 242.6 Hz), 136.9, 134.9, 129.6 (d, J = 5.1 Hz), 128.5 (2C), 128.5, 126.2 (2C), 125.4 (d, J = 8.4 Hz), 124.6 (d, J = 17.5 Hz), 114.7 (d, J = 22.5 Hz), 86.9, 79.9, 54.6, 51.9, 51.0, 39.7, 14.8 ppm.

¹⁹F NMR (471 MHz, CDCl₃) δ -119.16 ppm.

HRMS (ESI) calculate: C₂₀H₂₀FO₃⁺ (M+H)⁺: 327.1391, found: 327.1386.

Methyl 3-(benzofuran-4-yl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



48 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 5% EtOAc in PE to afford the title compound as a pale yellow solid. (28 mg, 0.083 mmol, 83%).

R_f = 0.3 (10% EtOAc in PE).


¹H NMR (500 MHz, CDCl₃) δ 7.73 (d, J = 1.7 Hz, 1H), 7.62 (d, J = 2.2 Hz, 1H), 7.57 – 7.52 (m, 2H), 7.49 – 7.33 (m, 6H), 6.76 (d, J = 2.2 Hz, 1H), 5.62 (s, 1H), 3.73 (s, 3H),

2.64 (dd, $J = 10.2, 7.1$ Hz, 1H), 2.56 (d, $J = 7.0$ Hz, 1H), 2.36 (dd, $J = 10.2, 8.1$ Hz, 1H), 2.24 (d, $J = 8.1$ Hz, 1H) ppm.

^{13}C NMR (126 MHz, CDCl_3) δ 170.6, 154.6, 145.4, 137.0, 134.1, 128.5 (2C), 128.4, 127.3, 126.3 (2C), 122.8, 119.4, 111.0, 106.8, 86.8, 80.6, 54.8, 51.9, 51.0, 39.7 ppm.

HRMS (ESI) calculate: $\text{C}_{21}\text{H}_{19}\text{O}_4^+$ ($\text{M}+\text{H}$) $^+$: 335.1278, found: 335.1273.

Methyl-3-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



49 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 5% EtOAc in PE to afford the title compound as a pale yellow solid. (21 mg, 0.063 mmol, 63%).


$R_f = 0.4$ (10% EtOAc in PE).

^1H NMR (400 MHz, CDCl_3) δ 7.52 – 7.45 (m, 2H), 7.44 – 7.31 (m, 3H), 6.99 (d, $J = 2.1$ Hz, 1H), 6.93 – 6.80 (m, 2H), 5.40 (s, 1H), 4.25 (s, 4H), 3.75 (s, 3H), 2.59 – 2.49 (m, 2H), 2.30 (t, $J = 9.2$ Hz, 1H), 2.21 (d, $J = 8.0$ Hz, 1H) ppm.

^{13}C NMR (101 MHz, CDCl_3) δ 170.5, 143.2, 143.1, 137.0, 132.8, 128.4 (2C), 128.3, 126.2 (2C), 119.4, 116.9, 115.6, 86.7, 79.9, 64.4, 54.6, 51.9, 50.8, 39.9 ppm.

HRMS (ESI) calculate: $\text{C}_{21}\text{H}_{21}\text{O}_5^+$ ($\text{M}+\text{H}$) $^+$: 353.1384, found: 353.1387.

Methyl-3-phenethyl-1-(*o*-tolyl)-2-oxabicyclo[2.1.1]hexane-4-carboxylate



50 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (21 mg, 0.065 mmol, 65%).

$R_f = 0.6$ (10% EtOAc in PE).


^1H NMR (500 MHz, CDCl_3) δ 7.30 (app. t, $J = 7.5$ Hz, 2H), 7.24 (d, $J = 8.0$ Hz, 3H), 7.22 – 7.16 (m, 4H), 4.33 (dd, $J = 9.6, 3.5$ Hz, 1H), 3.75 (s, 3H), 2.97 – 2.89 (m, 1H),

2.75 – 2.66 (m, 1H), 2.56 – 2.48 (m, 5H), 2.43 (d, $J = 6.6$ Hz, 1H), 2.28 (d, $J = 7.3$ Hz, 1H), 2.09 – 2.00 (m, 1H), 1.95 – 1.84 (m, 1H) ppm.

^{13}C NMR (151 MHz, CDCl_3) δ 171.0, 142.0, 137.9, 134.5, 131.1, 128.9, 128.5 (2C), 128.4 (2C), 127.6, 125.9, 125.7, 87.3, 79.8, 52.2, 51.9, 49.1, 41.3, 34.9, 32.2, 20.1 ppm.

HRMS (ESI) calculate: $\text{C}_{22}\text{H}_{25}\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$: 337.1798, found: 337.1794.

Methyl-3-phenethyl-1-(*o*-tolyl)-2-oxabicyclo[2.1.1]hexane-4-carboxylate



51 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (24 mg, 0.072 mmol, 72%).


$R_f = 0.6$ (10% EtOAc in PE).

^1H NMR (600 MHz, CDCl_3) δ 7.31 – 7.27 (m, 2H), 7.24 (dd, $J = 8.2, 1.6$ Hz, 3H), 7.21 – 7.17 (m, 2H), 7.14 (d, $J = 7.5$ Hz, 1H), 4.33 (dd, $J = 9.5, 3.6$ Hz, 1H), 3.74 (s, 3H), 2.98 – 2.90 (m, 1H), 2.76 – 2.69 (m, 1H), 2.42 – 2.36 (m, 4H), 2.36 – 2.28 (m, 2H), 2.26 – 2.20 (m, 1H), 2.07 – 2.00 (m, 1H), 1.92 – 1.84 (m, 1H) ppm.

^{13}C NMR (151 MHz, CDCl_3) δ 170.9, 142.0, 138.1, 137.1, 129.0, 128.5 (2C), 128.4 (2C), 128.3, 126.7, 125.8, 123.1, 86.5, 79.6, 52.6, 51.9, 49.9, 41.9, 34.8, 32.2, 21.4 ppm.

HRMS (ESI) calculate: $\text{C}_{22}\text{H}_{25}\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$: 337.1798, found: 337.1792.

Methyl-3-phenethyl-1-(*o*-tolyl)-2-oxabicyclo[2.1.1]hexane-4-carboxylate



52 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (26 mg, 0.078 mmol, 78%).


$R_f = 0.6$ (10% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.30 (dd, *J* = 11.0, 7.6 Hz, 4H), 7.27 – 7.23 (m, 2H), 7.23 – 7.17 (m, 3H), 4.33 (dd, *J* = 9.5, 3.5 Hz, 1H), 3.75 (s, 3H), 2.99 – 2.90 (m, 1H), 2.78 – 2.67 (m, 1H), 2.42 – 2.31 (m, 5H), 2.30 (d, *J* = 7.5 Hz, 1H), 2.27 – 2.21 (m, 1H), 2.09 – 1.99 (m, 1H), 1.92 – 1.84 (m, 1H) ppm.

¹³C NMR (151 MHz, CDCl₃) δ 170.9, 142.0, 138.1, 134.3, 129.0 (2C), 128.5 (2C), 128.4 (2C), 126.0 (2C), 125.9, 86.4, 79.5, 52.6, 51.9, 49.9, 41.9, 34.9, 32.2, 21.3 ppm.

HRMS (ESI) calculate: C₂₂H₂₅O₃⁺ (M+H)⁺: 337.1798, found: 337.1795.

Methyl-1-(4-fluorophenyl)-3-phenethyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



53 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (14 mg, 0.040 mmol, 40%).

R_f = 0.6 (10% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.41 – 7.35 (m, 2H), 7.31 – 7.27 (m, 2H), 7.24 (d, *J* = 7.6 Hz, 2H), 7.22 – 7.17 (m, 1H), 7.09 – 7.02 (m, 2H), 4.32 (dd, *J* = 9.6, 3.5 Hz, 1H), 3.74 (s, 3H), 2.97 – 2.89 (m, 1H), 2.76 – 2.68 (m, 1H), 2.39 (dd, *J* = 7.0, 1.7 Hz, 1H), 2.35 – 2.28 (m, 2H), 2.26 – 2.20 (m, 1H), 2.05 – 2.00 (m, 1H), 1.91 – 1.81 (m, 1H) ppm.

¹³C NMR (151 MHz, CDCl₃) δ 170.7, 162.6 (d, *J* = 246.9 Hz), 141.9, 133.1 (d, *J* = 3.4 Hz), 128.5 (2C), 128.4 (2C), 127.9 (d, *J* = 8.0 Hz, 2C), 125.9, 115.3 (d, *J* = 21.3 Hz, 2C), 85.8, 79.6, 52.6, 51.9, 49.9, 42.0, 34.7, 32.1 ppm.

¹⁹F NMR (471 MHz, CDCl₃) δ -113.62 ppm.

HRMS (ESI) calculate: C₂₁H₂₂FO₃⁺ (M+H)⁺: 341.1547, found: 341.1544.

Methyl-1-(4-chlorophenyl)-3-phenethyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



54 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (30 mg, 0.084 mmol, 84%).


$R_f = 0.6$ (10% EtOAc in PE).

$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.35 (s, 4H), 7.30 (t, $J = 7.5$ Hz, 2H), 7.27 – 7.23 (m, 2H), 7.23 – 7.18 (m, 1H), 4.33 (dd, $J = 9.5, 3.5$ Hz, 1H), 3.75 (s, 3H), 2.98 – 2.90 (m, 1H), 2.78 – 2.70 (m, 1H), 2.41 (d, $J = 6.9$ Hz, 1H), 2.32 (dd, $J = 9.9, 7.2$ Hz, 2H), 2.23 (dd, $J = 10.3, 7.6$ Hz, 1H), 2.10 – 2.00 (m, 1H), 1.93 – 1.83 (m, 1H) ppm.

$^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 170.6, 141.8, 135.8, 134.1, 128.6 (2C), 128.5 (2C), 128.4 (2C), 127.6 (2C), 125.9, 85.8, 79.6, 52.6, 52.0, 50.0, 42.1, 34.7, 32.2 ppm.

HRMS (ESI) calculate: $\text{C}_{21}\text{H}_{22}\text{ClO}_3^+$ ($\text{M}+\text{H}$) $^+$: 357.1252, found: 357.1254.

Methyl-1-(naphthalen-1-yl)-3-phenethyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



55 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (20 mg, 0.054 mmol, 54%).


$R_f = 0.6$ (10% EtOAc in PE).

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.39 (d, $J = 8.3$ Hz, 1H), 7.85 (dd, $J = 13.5, 8.1$ Hz, 2H), 7.57 – 7.48 (m, 2H), 7.46 – 7.41 (m, 1H), 7.37 (d, $J = 7.0$ Hz, 1H), 7.31 (t, $J = 7.5$ Hz, 2H), 7.26 (s, 2H), 7.23 – 7.18 (m, 1H), 4.48 (dd, $J = 9.4, 3.6$ Hz, 1H), 3.77 (s, 3H), 3.02 – 2.93 (m, 1H), 2.79 – 2.71 (m, 2H), 2.67 (t, $J = 8.9$ Hz, 1H), 2.53 (d, $J = 6.9$ Hz, 1H), 2.41 (d, $J = 7.6$ Hz, 1H), 2.18 – 2.09 (m, 1H), 2.06 – 1.98 (m, 1H) ppm.

^{13}C NMR (151 MHz, CDCl_3) δ 171.0, 142.1, 134.1, 132.9, 131.8, 129.8, 128.7 (2C), 128.6 (2C), 128.6 (2C), 126.3, 126.0, 126.0, 125.7, 125.1, 87.6, 80.4, 52.4, 52.1, 50.0, 42.2, 35.2, 32.3 ppm.

HRMS (ESI) calculate: $\text{C}_{25}\text{H}_{25}\text{O}_3^+$ (M+H) $^+$: 373.1798, found: 373.1800.

***Tert*-Butyl-3-phenethyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate**



56 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (31 mg, 0.085 mmol, 85%).


R_f = 0.5 (10% EtOAc in PE).

^1H NMR (500 MHz, CDCl_3) δ 7.41 (d, J = 6.9 Hz, 2H), 7.39 – 7.35 (m, 2H), 7.33 – 7.27 (m, 3H), 7.26 – 7.23 (m, 2H), 7.21 – 7.17 (m, 1H), 4.28 (dd, J = 9.5, 3.5 Hz, 1H), 2.99 – 2.91 (m, 1H), 2.79 – 2.71 (m, 1H), 2.36 (d, J = 6.9 Hz, 1H), 2.29 (dd, J = 10.1, 7.0 Hz, 1H), 2.25 (d, J = 7.6 Hz, 1H), 2.19 (dd, J = 10.1, 7.6 Hz, 1H), 2.08 – 2.00 (m, 1H), 1.92 – 1.83 (m, 1H), 1.47 (s, 9H) ppm.

^{13}C NMR (126 MHz, CDCl_3) δ 169.9, 142.2, 137.6, 128.6 (2C), 128.5 (2C), 128.4 (2C), 128.2, 126.2 (2C), 125.9, 86.2, 81.4, 79.6, 53.8, 50.0, 41.8, 34.9, 32.3, 28.2 (3C) ppm.

HRMS (ESI) calculate: $\text{C}_{24}\text{H}_{29}\text{O}_3^+$ (M+H) $^+$: 365.2111, found: 365.2113.

Phenyl-3-phenethyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



57 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (26 mg, 0.068 mmol, 68%).


R_f = 0.5 (10% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.46 (d, *J* = 7.2 Hz, 2H), 7.43 – 7.37 (m, 4H), 7.37 – 7.32 (m, 1H), 7.31 – 7.22 (m, 5H), 7.22 – 7.17 (m, 1H), 7.09 (d, *J* = 7.9 Hz, 2H), 4.48 (dd, *J* = 9.5, 3.6 Hz, 1H), 3.06 – 2.95 (m, 1H), 2.86 – 2.75 (m, 1H), 2.59 (d, *J* = 7.0 Hz, 1H), 2.49 (dd, *J* = 10.7, 7.2 Hz, 2H), 2.38 (dd, *J* = 10.3, 7.7 Hz, 1H), 2.24 – 2.12 (m, 1H), 2.04 – 1.93 (m, 1H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 168.9, 150.4, 141.9, 137.1, 129.7 (2C), 128.6 (2C), 128.6 (3C), 128.5, 126.3 (2C), 126.2 (2C), 126.0, 121.5 (2C), 86.7, 79.7, 52.9, 50.3, 42.3, 35.0, 32.3 ppm.

HRMS (ESI) calculate: C₂₆H₂₅O₃⁺ (M+H)⁺: 385.1798, found: 385.1796.

(1*R*,2*S*,5*R*)-2-Isopropyl-5-methylcyclohexyl-3-phenethyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



58 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford the title compound as a yellow oil. (41 mg, 0.089 mmol, 89%).


R_f = 0.8 (10% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.43 (dd, *J* = 7.5, 2.9 Hz, 2H), 7.41 – 7.35 (m, 2H), 7.35 – 7.27 (m, 3H), 7.24 (dd, *J* = 7.4, 2.5 Hz, 2H), 7.20 (app. t, *J* = 7.3 Hz, 1H), 4.79 – 4.71 (m, 1H), 4.33 (dd, *J* = 9.6, 2.4 Hz, 1H), 3.01 – 2.92 (m, 1H), 2.82 – 2.70 (m, 1H), 2.41 – 2.37 (m, 1H), 2.37 – 2.28 (m, 2H), 2.27 – 2.22 (m, 1H), 2.08 – 1.98 (m, 2H), 1.93 – 1.79 (m, 2H), 1.74 – 1.66 (m, 2H), 1.56 – 1.47 (m, 1H), 1.45 – 1.37 (m, 1H), 1.12 – 1.04 (m, 1H), 1.03 – 0.95 (m, 1H), 0.94 – 0.86 (m, 7H), 0.76 (dd, *J* = 7.0, 3.4 Hz, 3H). ppm.

¹³C NMR (126 MHz, CDCl₃) **Mixer of isomer 1 and isomer 2** δ 170.2, 170.1, 142.1, 137.5, 128.6, 128.6, 128.5, 128.3, 126.3, 126.2, 125.9, 86.5, 86.5, 79.7, 79.6, 74.9, 53.2, 50.1, 50.0, 47.1, 41.9, 41.8, 41.0, 35.0, 34.8, 34.3, 32.4, 32.3, 31.5, 26.7, 26.5, 23.7, 23.5, 22.2, 22.1, 20.9, 20.8, 16.6, 16.3 ppm.

HRMS (ESI) calculate: C₃₀H₃₉O₃⁺ (M+H)⁺: 447.2894, found: 447.2896.

(3*S*,8*S*,10*R*,13*S*,14*S*,17*S*)-17-Acetyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl 3-phenethyl-1-phenyl-2-oxabicyclo[2.1.1]hexane-4-carboxylate



59 was synthesized according to the general procedure C and purified by flash column chromatography (silica gel), eluting with 6% EtOAc in PE to afford the title compound as a yellow oil. (45 mg, 0.076 mmol, 76%).

R_f = 0.2 (10% EtOAc in PE).


¹H NMR (500 MHz, CDCl₃) δ 7.42 (dd, *J* = 8.3, 1.6 Hz, 2H), 7.40 – 7.35 (m, 2H), 7.34 – 7.27 (m, 3H), 7.25 (d, *J* = 6.7 Hz, 2H), 7.21 – 7.17 (m, 1H), 5.39 (d, *J* = 4.9 Hz, 1H), 4.73 – 4.65 (m, 1H), 4.32 (dd, *J* = 9.4, 3.5 Hz, 1H), 2.95 (s, 1H), 2.79 – 2.70 (m, 1H), 2.57 – 2.51 (m, 1H), 2.40 (d, *J* = 6.9 Hz, 1H), 2.35 – 2.28 (m, 4H), 2.23 (dd, *J* = 10.0, 7.6 Hz, 1H), 2.18 (dd, *J* = 11.1, 1.9 Hz, 1H), 2.13 (s, 3H), 2.08 – 1.98 (m, 3H), 1.93 – 1.84 (m, 3H), 1.72 – 1.60 (m, 4H), 1.54 – 1.44 (m, 3H), 1.28 – 1.13 (m, 4H), 1.03 (s, 4H), 0.64 (s, 3H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 209.7, 170.0, 142.1, 139.5, 137.4, 128.6 (2C), 128.5 (2C), 128.5 (2C), 128.3, 126.2 (2C), 126.0, 122.7, 86.4, 79.6, 74.4, 63.8, 56.9, 53.0, 50.1, 50.0, 44.1, 41.9, 38.9, 38.1, 37.1, 36.7, 34.8, 32.3, 31.9, 31.9, 31.7, 27.8, 24.6, 23.0, 21.2, 19.5, 13.3 ppm.

HRMS (ESI) calculate: C₄₁H₅₁O₄⁺ (M+H)⁺: 607.3782, found: 607.3782.

4 Mechanistic Studies

4.1 Radical cation trapping experiment




An oven-dried two-dram vials equipped with PTFE-coated stir bar and Teflon® septum were used. $\text{Mes}_2\text{Acr-tBu}_2\text{BF}_4$ (**PC1**, 0.6 mg, 0.005 mmol) and **1a** (38 mg, 0.2 mmol) were added into the vial and was dissolved in DCE (0.5 mL) under oxygen atmosphere. The vial was set to stir (500 rpm) and irradiated with a 30 W 450 nm blue LED lamp (approximate 3 cm away, with cooling fan to keep the reaction at room temperature). After 12 hours, the reaction mixture was transferred to a 100mL round-bottom flask and concentrated in vacuo. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with 10% EtOAc in PE to afford **60** as a pale-yellow oil (9 mg, 0.042 mmol, 21%)

$R_f = 0.6$ (20% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.98 – 7.92 (m, 2H), 7.63 – 7.56 (m, 1H), 7.48 (app. t, $J = 7.8$ Hz, 2H), 3.76 (s, 3H), 3.61 – 3.51 (m, 2H), 3.29 (d, $J = 5.6$ Hz, 1H), 2.92 (d, $J = 5.6$ Hz, 1H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 195.9, 170.3, 136.2, 133.8, 128.9 (2C), 128.2 (2C), 54.0, 53.0, 51.7, 41.7 ppm.

HRMS (ESI) calculate: $\text{C}_{12}\text{H}_{13}\text{O}_4^+$ ($\text{M}+\text{H}$) $^+$: 221.0808, found: 221.0807.



An oven-dried two-dram vials equipped with PTFE-coated stir bar and Teflon® septum were used. $\text{Mes}_2\text{Acr-tBu}_2\text{BF}_4$ (**PC1**, 0.6 mg, 0.005 mmol), **1a** (38 mg, 0.2 mmol) and MeOH (41 μL , 0.5 mmol) were added into the vial and was dissolved in DCE (1 mL). The vial was set to stir (500 rpm) and irradiated with a 30 W 450 nm blue LED lamp (approximate 3 cm away, with cooling fan to keep the reaction at room temperature). After 12 hours, the reaction mixture was transferred to a 100mL round-bottom flask and concentrated in vacuo. The crude reaction mixture

was purified by flash column chromatography (silica gel), eluting with 3% EtOAc in PE to afford **61** as a pale-yellow oil (13 mg, 0.030 mmol, 30%)

$R_f = 0.6$ (10% EtOAc in PE)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.39 – 7.33 (m, 2H), 7.32 – 7.26 (m, 3H), 3.66 (s, 3H), 3.41 – 3.33 (m, 1H), 2.98 (s, 3H), 2.65 (d, $J = 8.8$ Hz, 5H) ppm.

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 175.8, 142.5, 128.4 (2C), 127.6, 126.2 (2C), 80.0, 51.9, 51.1, 35.1 (2C), 32.2 ppm.

HRMS (ESI) calculate: $\text{C}_{13}\text{H}_{17}\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$: 221.1172, found: 221.1173.




Figure S6. HMBC spectrum of compound **61**


Note: the highlighted correlation (in red square) on the HMBC spectra belongs to H_{15} and C_{14} , and no correlations between H_{15} and any aromatic carbons could be observed. As such, the methoxy group should be adjacent to the benzyl group therefore suggesting the resulted trapping compound by MeOH is **61**.

4.2 Radical trapping experiment

According to general procedure C, depends on specific conditions, $\text{Mes}_2\text{Acr-}t\text{Bu}_2\text{BF}_4$ (**PC1**, 0.6 mg, 0.001 mmol), CoCl_2 (1 mg, 0.0075 mmol), **1a** (38 mg, 0.2

mmol), **2a** (12 μ L, 0.1 mmol), PBN (89 mg, 0.5 mmol) or TEMPO (78 mg, 0.5 mmol) were selectively used.

Condition A: Mes₂Acr-*t*Bu₂BF₄ (**PC1**, 0.6 mg, 0.001 mmol), CoCl₂ (1 mg, 0.0075 mmol), **1a** (38 mg, 0.2 mmol), **2a** (12 μ L, 0.1 mmol), PBN (89 mg, 0.5 mmol) under reaction conditions in general procedure C.



62 was detected by HRMS as illustrated below. **3** was purified by flash column chromatography (silica gel), eluting with 3% EtOAc in PE to afford **3** as a white solid (18 mg, 0.056 mmol, 56%). All analytical data match to the previous reported **3**.





Figure S7. HRMS spectrum and formula prediction of compound **62**

Condition B: Mes₂Acr-*t*Bu₂BF₄ (**PC1**, 0.6 mg, 0.001 mmol), **1a** (38 mg, 0.2 mmol), **2a** (12 μ L, 0.1 mmol), PBN (89 mg, 0.5 mmol) under reaction conditions in general procedure C.



62 was detected by HRMS as illustrated below. **3** was purified by flash column chromatography (silica gel), eluting with 3% EtOAc in PE to afford **3** as a white solid (8 mg, 0.025 mmol, 25%). All analytical data match to the previous reported **3**.





Figure S8. HRMS spectrum and formula prediction of compound **62**

Condition C: Mes₂Acr-*t*Bu₂BF₄ (**PC1**, 0.6 mg, 0.0005 mmol), CoCl₂ (1 mg, 0.00375 mmol), **1a** (38 mg, 0.2 mmol), PBN (89 mg, 0.25 mmol) under reaction conditions in general procedure C.



62 was purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford **63** as a pale-yellow oil (9 mg, 0.024 mmol, 12%).

R_f = 0.7 (10% EtOAc in PE)

¹H NMR (500 MHz, CDCl₃) δ 7.34 – 7.24 (m, 2H), 7.09 – 6.91 (m, 6H), 6.65 – 6.58 (m, 2H), 4.43 (s, 1H), 3.77 (s, 3H), 3.34 – 3.27 (m, 1H), 2.60 (dd, *J* = 9.3, 3.1 Hz, 1H), 2.35 – 2.26 (m, 2H), 1.08 (s, 9H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 170.3, 144.6, 142.2, 127.9, 127.6 (2C), 127.4 (2C), 126.8, 126.2 (2C), 126.1 (2C), 78.6, 72.6, 60.5, 52.4, 48.0, 45.0, 35.5, 26.8 (3C) ppm.

HRMS (ESI) calculate: C₂₃H₂₇NO₃⁺ (M+H)⁺: 366.2064, found: 366.2064.





Figure S9. HMBC spectrum of compound **62**


Note: the highlighted correlation (in red square) on the HMBC spectra belongs to H₅ and C₂, and no correlations between H₅ and C₁ (in blue square) could be observed. As such, the oxygen was linked to C₁ therefore suggesting the resulted trapping compound by PBN is **62**.

Condition D: Mes₂Acr-*t*Bu₂BF₄ (**PC1**, 0.6 mg, 0.0005 mmol), **1a** (38 mg, 0.2 mmol), PBN (87 mg, 0.25 mmol) under reaction conditions in general procedure C.



62 under condition D was purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to afford **62** as a pale-yellow oil (9 mg, 0.024 mmol, 12%). All analytical data match to the previous reported **62**.

Condition E: Mes₂Acr-*t*Bu₂BF₄ (**PC1**, 0.6 mg, 0.001 mmol), CoCl₂ (1 mg, 0.0075 mmol), **1a** (38 mg, 0.2 mmol), **2a** (12 μL, 0.1 mmol), TEMPO (78 mg, 0.5 mmol) under reaction conditions in general procedure C.



No **3** could be observed but **63** on HRMS was detected as below.




Figure S10. HRMS spectrum and formula prediction of compound **63**

4.3 Ketyl Radical-trapping Experiment

According to general procedure C, Mes₂Acr-*t*Bu₂BF₄ (**PC1**, 0.6 mg, 0.001 mmol), CoCl₂ (1 mg, 0.0075 mmol), **1a** (38 mg, 0.2 mmol) and (**±**)-*trans* **2x** (15 mg, 0.1 mmol) were used.



64 was purified by flash column chromatography (silica gel), eluting with 3% EtOAc in PE to afford **64** as a pale-yellow oil (21 mg, 0.063 mmol, 63%, 1.2:1 dr).

$R_f = 0.5$ (10% EtOAc in PE)

¹H NMR (500 MHz, CDCl₃) **Mixer of isomer 1 and isomer 2** δ 7.45 – 7.28 (m, 10H), 7.26 – 7.23 (m, 4H), 7.18 – 7.13 (m, 2H), 7.13 – 7.08 (m, 2H), 7.08 – 7.02 (m, 2H), 3.84 – 3.80 (m, 2H), 3.79 (s, 3H), 3.62 (s, 3H), 2.43 – 2.32 (m, 8H), 1.33 – 1.28 (m, 2H), 1.19 (dd, *J* = 8.8, 5.3 Hz, 1H), 1.17 – 1.13 (m, 1H), 1.03 – 0.95 (m, 2H) ppm.

Isomer 1 δ 2.13 – 2.07 (m, 1H), 1.03 – 0.95 (m, 2H) ppm. **Isomer 2** δ 1.98 – 1.93 (m, 1H), 1.19 (dd, *J* = 8.8, 5.3 Hz, 1H), 1.17 – 1.13 (m, 1H) ppm.

¹³C NMR (126 MHz, CDCl₃) **Mixer of isomer 1 and isomer 2** δ 171.1, 170.9, 142.4, 142.0, 137.0, 136.9, 128.5, 128.4, 128.4, 126.3, 126.1, 125.9, 125.8, 86.6, 86.4, 84.6, 84.5, 53.4, 53.3, 52.0, 49.9, 49.7, 42.1, 41.8, 24.7, 24.6, 21.4, 20.9, 13.7, 12.7 ppm.

HRMS (ESI) calculate: $C_{22}H_{23}O_3^+$ (M+H)⁺: 335.1642, found: 335.1639.

4.4 UV-Vis Absorption Spectra Analysis

UV-visible absorption spectra were carried out on the Agilent Cary 5000 UV-Vis-NIR spectrophotometer, equipped with a temperature control unit at 25 °C. All samples were measured in cuvettes (volume: 2.0 mL, path length: 10 mm) equipped with a PTFE stopper. The spectra were acquired from 350 to 700 nm using 1.0 nm steps. All measurements were performed in 2 mL of dry DCE with consistent concentration of 2.5 mM.




Figure S11. UV-Vis absorption spectra

4.5 Stern-Volmer Luminescence Quenching Analysis

Emission intensities were recorded using a Fluorolog-3 luminescence spectrometer. Solutions of different components were prepared and introduced to a 10 mm path length quartz cuvette in glovebox. Excitation bandwidth = 1 nm, data interval = 0.2 nm, scan speed = 500 nm/min, dwell time = 0.03 s. All the solution was excited at 400 nm and the emission intensity was collected at 510 nm. The solution of **PC1** (0.5 mM, 20 mL), **1a** (50 mM, 20 mL), **2a** (50 mM, 20 mL) were prepared in glovebox using a mixture of dry DCE. I_0 is the luminescence intensity without quenching substrates, and I is the intensity in the presence of quenching substrates. All intensity values were normalized by subtracting the basal intensity of blank DCE solvent.

For Experiment 1: Constant photocatalyst; Varied concentration of **1a**

Add 100 μL of **PC1** solution and 0 μL , 100 μL , 300 μL , 500 μL , 700 μL and 900 μL **1a** solution respectively in the quartz cuvette and then diluted the solution to 2 mL by using the mixture of dry DCE.

Comment: **1a** could quench the excited photocatalyst.




Figure S12. Emission of **PC1** with varying **1a** quencher concentrations

For Experiment 2: Constant photocatalyst; Varied concentration of **2a**

Add 100 μL of **PC1** solution and 0 μL , 100 μL , 300 μL , 500 μL , 700 μL and 900 μL **2a** solution respectively in the quartz cuvette and then diluted the solution to 2 mL by using the mixture of dry DCE.

Comment: **2a** could not quench the excited photocatalyst.




Figure S13. Emission of **PC1** with varying **2a** quencher concentrations




Figure S14. Stern-Volmer plots of **1a** and **2a**

4.6 Quantum Yield Experiment

According to our previous literature procedure, the photo flux of the 30 W 450 nm LED lamp was first determined by standard ferrioxalate actinometry.^[7]

Preparation of 0.15 M solution of ferrioxalate (0.15 M):

Potassium ferrioxalate trihydrate (1474 mg) was dissolved in H₂SO₄ aq. (20 mL, 0.2M).

Preparation of buffered solution (0.15 M):

1,10-phenanthroline (541 mg, 3.0 mmol), NaOAc (1.23 g, 15.0 mmol) were dissolved in H₂SO₄ aq. (20 mL, 0.2M). To two 8 mL vials added ferrioxalate solution (1 mL) respectively and irradiated one of the vials with an LED lamp (30W, 450 nm) while the other kept in dark. After 30 s, buffered solution (3 mL) and H₂SO₄ aq. (2 mL, 0.2M) were added immediately to both vials. The resulting mixtures were kept in dark for another 1 h to allow the formed ferrous ions completely coordinate to the phenanthroline. Then, 25 μ L of each resulting mixture was transferred to a cuvette ($l = 10$ mm) and diluted with H₂SO₄ aq. (2 mL, 0.2 M). The absorbance at 510 nm was measured by UV-vis spectrometry. The photo flux was measured by following equation:

$$\text{mol Fe}^{2+} = \frac{V \times \Delta A (510 \text{ nm})}{l \times \epsilon}$$

Where V is the total volume (0.486 L) of the solution after addition of phenanthroline, $\Delta A = 0.1895$ is the difference in absorbance at 510 nm between

the irradiated and non-irradiated solutions, l is the path length (1.0 cm), and ϵ is the molar absorptivity at 510 nm ($11,100 \text{ L}\cdot\text{mol}^{-1}\cdot\text{cm}^{-1}$). The photon flux can be calculated as following equation:

$$\text{photon flux} = \frac{\text{mol Fe}^{2+}}{\Phi \times t \times f}$$

Where Φ is the quantum yield for the ferrioxalate actinometer (approximate 0.845 for a 0.15 M solution at $\lambda = 450 \text{ nm}$), t is the time (30 s), and f is the fraction of light absorbed at $\lambda = 450 \text{ nm}$ by the ferrioxalate actinometer. This value is calculated using the following equation where $A(450 \text{ nm})$ is the absorption of the ferrioxalate solution at 450 nm. An absorption spectrum gave an $A(450 \text{ nm}) = 0.1343$, indicating that the fraction of absorbed light (f) = 0.26601.

$$f = 1 - 10^{-A(450 \text{ nm})} = 1 - 10^{-0.1343} = 0.2660$$

The photon flux was calculated to be $1.230 \times 10^{-6} \text{ einstein}\cdot\text{s}^{-1}$.





Figure S15. UV-Vis spectrum of quantum yield

Determination of quantum yield



An oven-dried two-dram vials equipped with PTFE-coated stir bar and Teflon® septum were used. To the vial was added **1a** (38 mg, 0.2 mmol), **2a** (13 μL , 0.1 mmol), CoCl_2 (1.0 mg, 0.075 mmol), $\text{Mes}_2\text{Acr-tBu}_2\text{BF}_4$ (**PC1**, 0.7 mg, 0.001 mmol) and were dissolved by DCE (0.5 mL). The mixture was set to stir (500 rpm) and

irradiated with a 30 W 450 nm blue LED lamp (approximate 3 cm away, with cooling fan to keep the reaction at room temperature). After 3 minutes, the reaction mixture was transferred to a 100 mL round-bottom flask and concentrated in vacuo. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with 2% EtOAc in PE to give the desired product as a pale-yellow oil (10 mg, 0.033 mmol, 33%) and the quantum yield is calculated by the following equation:

$$\Phi = \frac{\text{mol product}}{\text{flux} \times t \times f}$$

where flux is the photon flux determined by ferrioxalate actinometry (1.230×10^{-6} einsteins. s^{-1}), t is the time (180 s), and f is the fraction of light absorbed by the reaction mixture at 450 nm. This value is calculated using eq. 3 where $A(450\text{nm})$ is the absorption of the ferrioxalate solution at 450 nm. f is the fraction of light absorbed at $\lambda = 450$ nm (0.935, $A = 1.18591$).

$$\Phi = \frac{\text{mol product}}{\text{flux} \times t \times f} = \frac{3.3 \times 10^{-5} \text{ mol}}{1.230 \times 10^{-6} \text{ einstein} \cdot 10^{-1} \times 600 \text{ s} \times 0.935} = 0.1594$$

5 Gram-scale experiment

According to the General procedure C, **1a** (1.88 g, 10 mmol) and **2a** (0.66 mL, 5 mmol) were used and reacted in 200 mL Schlenk tubes instead of two-dram vials. Upon completion, the crude reaction mixture was purified by flash column chromatography (silica gel), eluting with 3% EtOAc in PE to give compound **3** (1.48 g, 4.60 mmol, 92%).





Figure S16. Pictures of gram-scale reaction and compound **3**

6 Synthetic Transformation



Compound **65** was synthesized according to published procedures.^[2]


Compound **3** (32 mg, 0.1 mmol) was dissolved in anhydrous toluene (3 mL). Morpholine (18 μ L, 0.2 mmol) and LiHMDS (0.2 mL from 1 M solution in THF, 0.2 mmol) were added under nitrogen atmosphere. The mixture was stirred for 12 hours under nitrogen atmosphere at RT. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (3 \times 20 mL). The organic phases were combined, dried over NaSO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with 15% EtOAc in PE to give **65** (31 mg, 0.082 mmol, 82%) as a pale-yellow oil.

R_f = 0.4 (40% EtOAc in PE)

¹H NMR (500 MHz, CDCl₃) δ 7.39 (dd, *J* = 13.0, 5.7 Hz, 4H), 7.35 – 7.27 (m, 3H), 7.25 – 7.18 (m, 3H), 4.21 (dd, *J* = 8.9, 3.9 Hz, 1H), 3.75 – 3.67 (m, 2H), 3.67 – 3.53 (m, 3H), 3.39 (dd, *J* = 18.9, 10.4 Hz, 3H), 2.96 – 2.88 (m, 1H), 2.77 – 2.68 (m, 1H), 2.46 (d, *J* = 7.1 Hz, 1H), 2.40 (dd, *J* = 10.3, 7.9 Hz, 1H), 2.30 (dd, *J* = 15.9, 7.3 Hz, 2H), 2.09 – 1.99 (m, 1H), 1.93 – 1.83 (m, 1H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 168.8, 141.6, 137.0, 128.7 (2C), 128.6 (2C), 128.5 (2C), 128.4, 126.2 (2C), 126.1, 85.4, 79.4, 67.0, 66.9, 54.7, 50.5, 45.8, 43.4, 42.6, 34.6, 32.1 ppm.

HRMS (ESI) calculate: C₂₄H₂₈NO₃⁺ (M+H)⁺: 378.2064, found: 378.2058.



Compound **66** was synthesized according to adapted procedures.^[8]

Compound **3** (32 mg, 0.1 mmol) was dissolved in anhydrous THF (5 mL). BH₃ (0.25 mL from 1 M solution in THF) were added under nitrogen atmosphere. The


mixture was stirred for 12 hours under nitrogen atmosphere at 60 °C. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (3 × 20 mL). The organic phases were combined, dried over NaSO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with 15% EtOAc in PE to give **66** (28 mg, 0.096 mmol, 96%) as a pale-yellow oil.

R_f = 0.5 (30% EtOAc in PE)

¹H NMR (500 MHz, CDCl₃) δ 7.46 – 7.41 (m, 2H), 7.36 (dd, *J* = 8.5, 6.7 Hz, 2H), 7.33 – 7.27 (m, 3H), 7.27 – 7.23 (m, 2H), 7.22 – 7.16 (m, 1H), 4.08 (dd, *J* = 9.6, 3.5 Hz, 1H), 3.83 (d, *J* = 1.3 Hz, 2H), 3.03 – 2.92 (m, 1H), 2.78 – 2.67 (m, 1H), 2.09 (d, *J* = 6.8 Hz, 1H), 2.03 (dd, *J* = 10.1, 7.0 Hz, 1H), 1.99 – 1.86 (m, 3H), 1.85 – 1.76 (m, 1H), 1.70 (s, 1H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 142.4, 138.3, 128.6 (2C), 128.5 (2C), 128.4 (2C), 128.0, 126.2 (2C), 125.9, 86.8, 79.5, 61.4, 53.2, 46.4, 40.4, 34.8, 32.5 ppm.

HRMS (ESI) calculate: C₂₀H₂₃O₃⁺(M+H)⁺: 295.1693, found: 295.1690.



Compound **67** was synthesized according to adapted procedures.^[2]

Compound **66** (29 mg, 0.1 mmol) was dissolved in anhydrous THF (5 mL). DPPA (43 μL, 0.2 mmol) and DBU (45 μL, 0.3 mmol) were added under nitrogen atmosphere. The mixture was stirred for 48 hours under nitrogen atmosphere at 60 °C. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (3 × 20 mL). The organic phases were combined, dried over NaSO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with 6% EtOAc in PE to give **67** (22 mg, 0.069 mmol, 69%) as a pale-yellow oil.


R_f = 0.8 (20% EtOAc in PE)

¹H NMR (500 MHz, CDCl₃) δ 7.36 (d, *J* = 6.9 Hz, 2H), 7.30 (app. t, *J* = 7.4 Hz, 2H), 7.24 (dd, *J* = 9.3, 5.4 Hz, 3H), 7.21 – 7.16 (m, 2H), 7.16 – 7.11 (m, 1H), 4.00 (dd, *J* =

9.9, 3.3 Hz, 1H), 3.50 (d, $J = 5.5$ Hz, 2H), 2.92 (dd, $J = 6.8, 3.6$ Hz, 1H), 2.74 – 2.60 (m, 1H), 2.08 (d, $J = 7.0$ Hz, 1H), 2.02 (dd, $J = 10.1, 6.9$ Hz, 1H), 1.95 (dd, $J = 10.2, 7.2$ Hz, 1H), 1.90 (d, $J = 7.3$ Hz, 1H), 1.81 (dd, $J = 6.6, 3.4$ Hz, 1H), 1.78 – 1.67 (m, 1H) ppm.

^{13}C NMR (126 MHz, CDCl_3) δ 142.2, 137.9, 128.6 (2C), 128.6 (2C), 128.4 (2C), 128.2, 126.2 (2C), 126.0, 87.0, 79.6, 51.4, 51.2, 47.5, 41.6, 34.5, 32.4 ppm.

HRMS (ESI) calculate: $\text{C}_{20}\text{H}_{22}\text{NO}^+(\text{M}+\text{H}-\text{N}_2)^+$: 292.1696, found: 292.1692.




68 was synthesized according to the general procedure B and purified by flash column chromatography (silica gel), eluting with 3% MeOH in DCM to afford **68** as a colourless oil (30 mg, 0.097 mmol, 97%).

$R_f = 0.6$ (6% MeOH in DCM)

^1H NMR (500 MHz, MeOD) δ 7.45 – 7.40 (m, 2H), 7.39 – 7.34 (m, 2H), 7.33 – 7.29 (m, 1H), 7.29 – 7.22 (m, 4H), 7.18 – 7.13 (m, 1H), 4.26 (dd, $J = 9.3, 3.7$ Hz, 1H), 2.94 – 2.85 (m, 1H), 2.77 – 2.68 (m, 1H), 2.44 (d, $J = 6.6$ Hz, 1H), 2.30 (d, $J = 7.2$ Hz, 1H), 2.29 – 2.19 (m, 2H), 2.09 – 2.00 (m, 1H), 1.92 – 1.82 (m, 1H) ppm.

^{13}C NMR (126 MHz, MeOD) δ 174.6, 143.2, 138.7, 129.5 (2C), 129.4 (2C), 129.3 (2C), 129.2, 127.2 (2C), 126.9, 87.8, 81.0, 54.2, 50.7, 42.6, 36.0, 33.2 ppm.

HRMS (ESI) calculate: $\text{C}_{22}\text{H}_{27}\text{O}_2^+(\text{M}+\text{H})^+$: 309.1485, found: 309.1486.



Compound **69** was synthesized according to adapted procedures.^[9]

Compound **3** (32 mg, 0.1 mmol) was dissolved in anhydrous THF (3 mL). MeLi (0.25 mL from 2 M solution in THF, 0.5 mmol) was added under nitrogen atmosphere. The mixture was stirred for 12 hours under nitrogen atmosphere at 40 °C. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (3 × 20 mL). The organic phases were combined, dried over NaSO₄, filtered


and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with 10% EtOAc in PE to give **69** (30 mg, 0.093 mmol, 93%) as a pale-yellow oil.

R_f = 0.5 (20% EtOAc in PE)

¹H NMR (500 MHz, CDCl₃) δ 7.44 (d, J = 7.5 Hz, 2H), 7.37 (app. t, J = 7.5 Hz, 2H), 7.33 – 7.24 (m, 5H), 7.19 (app. t, J = 6.8 Hz, 1H), 4.12 (dd, J = 11.0, 2.5 Hz, 1H), 3.08 – 2.98 (m, 1H), 2.79 – 2.70 (m, 1H), 2.17 – 2.06 (m, 2H), 2.04 – 1.98 (m, 2H), 1.98 – 1.95 (m, 1H), 1.88 – 1.75 (m, 1H), 1.30 (s, 3H), 1.27 (s, 3H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 142.7, 138.7, 128.7 (2C), 128.5 (2C), 128.4 (2C), 127.9, 126.2 (2C), 125.8, 84.5, 79.5, 70.0, 59.0, 46.5, 38.7, 35.9, 32.7, 27.8, 26.6 ppm.

HRMS (ESI) calculate: C₂₂H₂₇O₂⁺(M+H)⁺: 323.2006, found: 323.2004.



Compound **70** was synthesized according to published procedures.^[10]


Compound **3** (32 mg, 0.1 mmol) was dissolved in anhydrous THF (5 mL). Ti(OiPr)₄ (41 μ L, 0.14 mmol) and EtMgBr (0.14 mL from a 2M solution in THF, 0.28 mmol) were added under nitrogen atmosphere. The mixture was stirred for 12 hours under nitrogen atmosphere at RT. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (3 \times 20 mL). The organic phases were combined, dried over NaSO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with 10% EtOAc in PE to give **70** (18 mg, 0.056 mmol, 56%) as a pale-yellow oil.

R_f = 0.4 (20% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) δ 7.42 (d, J = 7.2 Hz, 2H), 7.37 (app. t, J = 7.4 Hz, 2H), 7.30 (d, J = 6.7 Hz, 5H), 7.23 – 7.18 (m, 1H), 4.30 (dd, J = 9.6, 3.4 Hz, 1H), 3.06 – 2.97 (m, 1H), 2.86 – 2.76 (m, 1H), 2.24 – 2.11 (m, 2H), 1.96 – 1.89 (m, 2H), 1.89 – 1.79 (m, 2H), 1.61 (s, 1H), 0.90 – 0.82 (m, 1H), 0.81 – 0.73 (m, 1H), 0.70 – 0.64 (m, 1H), 0.64 – 0.54 (m, 1H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 142.7, 138.4, 128.7 (2C), 128.5 (2C), 128.4 (2C), 128.1, 126.2 (2C), 125.9, 85.7, 80.2, 54.8, 54.7, 47.1, 41.0, 35.2, 32.7, 12.4, 11.1 ppm.

HRMS (ESI) calculate: C₂₂H₂₄O₂⁺(M+H)⁺: 321.1849, found: 321.1849.



Compound **68** (31 mg, 0.1 mmol) was dissolved in DCM (5 mL). Atomoxetine hydrochloride (35 mg, 0.12 mmol), EDCI·HCl (29 mg, 0.15 mmol) and DMAP (2 mg, 0.02 mmol) were added under nitrogen atmosphere. The mixture was stirred for 12 hours under nitrogen atmosphere at RT. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (3 × 20 mL). The organic phases were combined, dried over NaSO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with 20% EtOAc in PE to give **71** (50 mg, 0.092 mmol, 92%) as a colorless oil.

R_f = 0.6 (50% EtOAc in PE).

¹H NMR (500 MHz, CDCl₃) **Mixer of isomer 1 and isomer 2** δ 7.42 – 7.29 (m, 15H), 7.28 – 7.21 (m, 10H), 7.21 – 7.15 (m, 5H), 7.12 (dd, *J* = 12.1, 6.0 Hz, 2H), 7.00 – 6.90 (m, 2H), 6.83 – 6.74 (m, 2H), 6.61 – 6.50 (m, 2H), 5.24 – 5.12 (m, 2H), 3.48 – 3.32 (m, 2H), 2.97 – 2.79 (m, 8H), 2.75 – 2.58 (m, 2H), 2.34 (d, *J* = 4.9 Hz, 9H), 2.29 – 2.10 (m, 8H), 2.09 – 1.92 (m, 3H), 1.92 – 1.77 (m, 2H) ppm. **Isomer 1** δ 4.32 – 4.27 (m, 1H), 3.73 – 3.62 (m, 1H) ppm. **Isomer 2** δ 4.23 – 4.12 (m, 1H), 3.59 – 3.48 (m, 1H) ppm.


¹³C NMR (126 MHz, CDCl₃) **Mixer of isomer 1 and isomer 2** δ 170.2, 170.1, 155.9, 155.5, 141.9, 141.8, 141.7, 141.7, 140.8, 137.4, 131.1, 130.9, 129.1, 128.9, 128.7, 128.6, 128.5, 128.4, 128.2, 127.9, 127.1, 126.9, 126.9, 126.4, 126.3, 126.1, 125.9, 125.8, 125.7, 120.9, 120.6, 112.9, 112.8, 112.7, 112.6, 85.3, 85.2, 85.2, 79.7, 79.7, 79.4, 77.7, 77.7, 76.8, 55.1, 54.8, 50.6, 50.6, 46.3, 46.0, 45.9, 43.6, 43.5, 43.4, 43.3, 37.9, 37.7, 36.4, 35.4, 35.2, 34.8, 34.7, 34.6, 33.9, 33.9, 32.3, 32.3, 17.1, 17.0, 16.8.

HRMS (ESI) calculate: C₃₇H₄₀NO₃⁺(M+H)⁺: 546.3003, found: 546.3003.

7 Physicochemical Property Assessment

The physicochemical property of Atomoxetine, **71**, Leelamine and **72** were calculated and predicted by different software and program. ClogP and tPSA values were generated by ChemDraw Office. pKa Values were predicted by a published graph-convolutional neural network program MolGpKa.^[11] Human plasma stabilities were predicted by a published attention-based graph neural network program PredPS.^[12] **71** and **72** were further measured the stability under different acidic conditions. Compound (55 mg for **71**, 58 mg for **72**, 0.1 mmol) were dissolved in THF (0.5 mL). Different concentration of HCl (2 mL from 0.2 M, 2 M or concentrated HCl aqueous solution) were added under nitrogen atmosphere. The mixture was stirred for 24 hours under nitrogen atmosphere at 37 °C. The reaction mixture was quenched with saturated NaHCO₃ aqueous solution (20 mL) and extracted with EtOAc (3 × 20 mL). The organic phases were combined, dried over NaSO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with indicated solvent system to give the desired compound and calculated the recovery ratio based on recovered **71** and **72**.

8 Phrenological Property Assessment




75 (15 mg, 0.032 mmol) was dissolved in DCM (5 mL). **76** (11 mg, 0.038 mmol), EDCI·HCl (9 mg, 0.048 mmol) and DMAP (0.8 mg, 0.006 mmol) were added under nitrogen atmosphere. The mixture was stirred for 12 hours under nitrogen atmosphere at RT. The reaction mixture was quenched with H₂O (10 mL) and extracted with EtOAc (3 × 10 mL). The organic phases were combined, dried over NaSO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with 1% MeOH in DCM to give **73** (14 mg, 0.019 mmol, 59%) as a colorless oil.

R_f = 0.6 (6% MeOH in DCM)

¹H NMR (500 MHz, CDCl₃) δ 7.45 (d, *J* = 7.4 Hz, 2H), 7.41 (d, *J* = 7.5 Hz, 2H), 7.34 (app. t, *J* = 7.5 Hz, 2H), 7.31 – 7.25 (m, 3H), 7.23 (d, *J* = 7.7 Hz, 3H), 7.20 – 7.15 (m, 3H), 6.69 – 6.61 (m, 2H), 6.50 (d, *J* = 8.1 Hz, 1H), 5.47 (s, 1H), 4.51 (s, 1H), 3.78 (s, 3H), 3.19 – 3.06 (m, 4H), 3.02 – 2.91 (m, 3H), 2.65 – 2.54 (m, 2H), 2.51 (d, *J* = 7.4 Hz, 1H), 2.25 (tt, *J* = 33.2, 11.1 Hz, 5H), 2.06 (dd, *J* = 13.0, 7.3 Hz, 2H), 1.66 (d, *J* = 12.7 Hz, 1H), 1.62 – 1.53 (m, 1H), 1.37 (td, *J* = 13.1, 5.7 Hz, 1H), 1.27 – 1.20 (m, 1H), 0.83 – 0.76 (m, 1H), 0.71 – 0.64 (m, 1H), 0.37 (p, *J* = 9.8 Hz, 2H), 0.04 – -0.04 (m, 2H) ppm.

¹³C NMR (126 MHz, CDCl₃) δ 168.0, 147.1, 141.9, 139.4, 138.9, 136.9, 135.3, 132.9, 130.1 (2C), 128.8, 128.6 (2C), 128.6, 128.4 (2C), 128.1, 126.7 (2C), 126.3 (2C), 120.0 (2C), 119.1, 113.7, 93.3, 86.1, 80.9, 77.1, 60.0, 58.7, 57.0, 56.7, 51.2, 49.9, 46.2, 44.0, 43.4, 40.4, 36.5, 36.2, 35.8, 29.8, 22.9, 18.8, 9.6, 4.2, 3.5 ppm.

HRMS (ESI) calculate: C₄₈H₅₁N₂O₅⁺ (M+H)⁺: 735.3792, found: 735.3794.



76 (15 mg, 0.032 mmol) was dissolved in DCM (5 mL). **77** (10 mg, 0.038 mmol), EDCI·HCl (9 mg, 0.048 mmol) and DMAP (0.8 mg, 0.006 mmol) were added under nitrogen atmosphere. The mixture was stirred for 12 hours under nitrogen atmosphere at RT. The reaction mixture was quenched with H₂O (10 mL) and extracted with EtOAc (3 × 10 mL). The organic phases were combined, dried over NaSO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (silica gel), eluting with 1% MeOH in DCM to give **74** (15 mg, 0.021 mmol, 66%) as a colorless oil.

R_f = 0.6 (6% MeOH in DCM)

¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J* = 2.0 Hz, 1H), 7.76 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.68 (dd, *J* = 7.8, 1.5 Hz, 2H), 7.54 – 7.37 (m, 9H), 7.21 (d, *J* = 8.2 Hz, 2H), 7.09 (d, *J* = 8.3 Hz, 2H), 6.99 (s, 1H), 6.72 (d, *J* = 8.1 Hz, 1H), 6.58 (d, *J* = 8.1 Hz, 1H), 4.59 (d, *J* = 2.0 Hz, 1H), 3.87 (s, 3H), 3.16 (s, 4H), 3.10 – 2.99 (m, 3H), 2.65 (dd, *J* = 11.9, 5.2 Hz, 1H), 2.32 (d, *J* = 6.5 Hz, 2H), 2.28 (d, *J* = 6.8 Hz, 1H), 2.14 (d, *J* = 5.4 Hz, 1H), 1.77 – 1.71 (m, 1H), 1.59 (dd, *J* = 13.9, 6.0 Hz, 2H), 1.49 – 1.41 (m, 1H), 1.35 – 1.27 (m, 2H), 0.90 – 0.84 (m, 1H), 0.81 – 0.71 (m, 1H), 0.51 – 0.41 (m, 2H), 0.08 (d, *J* = 5.0 Hz, 2H) ppm.

¹³C NMR (151 MHz, CDCl₃) δ 167.1, 147.1, 142.0, 140.9, 139.8, 139.8, 138.7, 138.5, 135.9, 135.9, 133.0, 131.1, 130.0 (2C), 129.2, 129.2 (2C), 129.1 (2C), 129.0 (2C), 128.8, 128.3 (2C), 128.0, 127.2 (2C), 120.0 (2C), 119.1, 113.8, 93.4, 77.1, 60.0, 58.8, 56.8, 51.2, 46.2, 44.0, 43.4, 36.5, 36.2, 35.8, 29.8, 22.9, 18.8, 9.6, 4.2, 3.5 ppm.

HRMS (ESI) calculate: C₄₉H₄₉N₂O₄⁺ (M+H)⁺: 729.3684, found: 729.3685.

Cell Membrane Preparation. Chinese hamster ovary (CHO) cells stably expressing human KOR, rat MOR or rat DOR were clustered in F12 medium with 10% fetal calf serum and 0.25 mg/mL G418. Cells were incubated in a humidified atmosphere consisting of 5% CO₂ and 95% air at 37 °C and detached by incubation

with phosphate buffered saline (PBS) containing 1 mM EDTA and then centrifuged at 1000g for 10 min, when cell growth reached 90% confluence. The cell pellets were suspended in ice-cold homogenization buffer (pH 7.4) containing 50 mM HEPES, 1 mM MgCl₂ and 1 mM EGTA. After homogenization with a glass dounce homogenizer, the pellets were centrifuged at 40,000 g for 30 min (4 °C). This producer including resuspension, homogenization, and centrifugation was repeated for twice more. The final pellets were resuspended in a 50 mM Tris-HCl buffer, pH 7.4. Protein concentration was determined, and aliquots were stored at -80 °C.


Radioligand Binding Assays. K_i value was measured according to a published literature.^[13] Competitive binding assays were carried out using [³H]U69593 (39.1 Ci/mmol) for KOR with K_d values of 0.7 ± 0.2 nM and B_{max} values of 871.3 ± 80.4 fmol/mg protein. Competition inhibition by compounds showing [³H]-labeled ligand binding to opioid receptors was performed in the absence or presence of test compounds at various concentrations. U50,488H at a concentration of 10 μM was used to define nonspecific binding. Assay was performed in 50 mM Tris-HCl buffer (pH 7.4) at 37 °C for 30 min in triplicate with a final volume of 0.5 mL containing 30 μg of membrane protein. After reaching equilibrium, bound and free [³H]-labeled ligands were separated by filtration under reduced pressure with GF/B filters. The radioactivity retained on the filters was counted by liquid scintillation counting. Binding data and K_i values were determined using the GraphPad Prism 10.2.

9 Docking Analysis


Docking analysis of **73** and **74** were followed to a published protocol.^[13] To reveal the binding model of compound **73** and **74**, we built a complex of compound **73** and **74** and opioid receptors based on the published crystal structures of KOR (PDB entry: 6B73). Original compound MP1104 were removed from the crystal structure and all hydrogen atoms added. The chemical structures of compounds **73** and **74** were sketched in SYBYL (Tripos, St Louis, MO, USA) and protonated, if appropriate, before energy minimization using the Tripos force field (Gasteiger-Hückel charges, distance-dependent dielectric constant = 4.0, nonbonded interaction cutoff = 8 Å and termination criterion = energy gradient < 0.05 kcal / (mol × Å) for 10 000 iterations). The molecular docking was performed using GOLD Suite 5.1 (Cambridge Crystallographic Data Centre, Cambridge, U.K.). The original ligand was extracted and the new ligands (compound **73** and **74**) were fit into the binding pocket of MP1104 in KOR. The ChemScore and GoldScore fitness scoring functions were utilized to identify lowest energy binding poses. The exported complexes were edited using UCSF Chimera.

10 X-Ray Structure of Compound 33

CCDC 2389698



33



Bond precision: C-C = 0.0023 Å Wavelength=1.34138
Cell: a=10.8872 (3) b=8.5462 (3) c=32.7304 (10)
alpha=90 beta=90 gamma=90
Temperature: 150 K

	Calculated	Reported
Volume	3045.37 (17)	3045.37 (16)
Space group	P b c a	P b c a
Hall group	-P 2ac 2ab	-P 2ac 2ab
Moiety formula	C19 H18 O3	C19 H18 O3
Sum formula	C19 H18 O3	C19 H18 O3
Mr	294.33	294.33
Dx, g cm ⁻³	1.284	1.284
Z	8	8
Mu (mm ⁻¹)	0.440	0.440
F000	1248.0	1248.0
F000'	1250.87	
h, k, lmax	13, 10, 40	13, 10, 40
Nref	3129	3104
Tmin, Tmax		0.635, 0.751
Tmin'		

Correction method= # Reported T Limits: Tmin=0.635 Tmax=0.751
AbsCorr = NONE

Data completeness= 0.992 Theta(max)= 57.018

R(reflections)= 0.0538 (2737) wR2(reflections)=
0.1224 (3104)
S = 1.112 Npar= 200

Figure S17. Crystal structure of compound **33** and XRD information

11 Unsuccessful Cases




Figure S18. Unsuccessful cases in scope section

12 NMR Spectra of Starting Materials




Figure S19. ¹H NMR spectra of **2y**




Figure S20. ¹³C NMR spectra of **2y**




Figure S21. ¹H NMR spectra of **2aa**




Figure S22. ¹³C NMR spectra of **2aa**




Figure S23. ¹H NMR spectra of **2ad**




Figure S24. ¹³C NMR spectra of **2ad**




Figure S25. ¹H NMR spectra of **2ae**




Figure S26. ¹³C NMR spectra of **2ae**




Figure S27. ¹H NMR spectra of **76**




Figure S28. ¹³C NMR spectra of **76**




Figure S29. ¹H NMR spectra of **77**




Figure S30. ¹³C NMR spectra of **77**

13 NMR Spectra of Desired Compounds




Figure S31. ¹H NMR spectra of **3**




Figure S32. ¹³C NMR spectra of **3**




Figure S33. ¹H NMR spectra of 4




Figure S34. ¹³C NMR spectra of 4




Figure S35. ¹⁹F NMR spectra of **4**




Figure S36. ¹H NMR spectra of **5**




Figure S37. ^{13}C NMR spectra of **5**




Figure S38. ^1H NMR spectra of **6**




Figure S39. ^{13}C NMR spectra of 6





Figure S40. ^1H NMR spectra of 7






Figure S41. ^{13}C NMR spectra of **7**



8

Figure S42. ^1H NMR spectra of **8**




Figure S43. ¹³C NMR spectra of **8**




Figure S44. ¹H NMR spectra of **9**




Figure S45. ^{13}C NMR spectra of **9**




Figure S46. ^1H NMR spectra of **10**




Figure S47. ^{13}C NMR spectra of **10**





Figure S48. ^1H NMR spectra of **11**




Figure S49. ^{13}C NMR spectra of **11**




Figure S50. ^1H NMR spectra of **12**




Figure S51. ¹³C NMR spectra of **12**





Figure S52. ¹H NMR spectra of **13**




Figure S53. ^{13}C NMR spectra of **13**




Figure S54. ^1H NMR spectra of **14**




Figure S55. ¹³C NMR spectra of **14**




Figure S56. ¹H NMR spectra of **15**




Figure S57. ^{13}C NMR spectra of **15**




Figure S58. ^1H NMR spectra of **16**




Figure S59. ¹³C NMR spectra of **16**





Figure S60. ¹H NMR spectra of **17**




Figure S61. ^{13}C NMR spectra of **17**




Figure S62. ^1H NMR spectra of **18**




Figure S63. ¹³C NMR spectra of **18**




Figure S64. ¹H NMR spectra of **19**




Figure S65. ^{13}C NMR spectra of **19**




Figure S66. ^1H NMR spectra of **20**




Figure S67. ^{13}C NMR spectra of **20**




Figure S68. ^1H NMR spectra of **21**




Figure S69. ¹³C NMR spectra of **21**




Figure S70. ¹H NMR spectra of **22**




Figure S71. ^{13}C NMR spectra of 22




Figure S72. ^1H NMR spectra of 23




Figure S73. ¹³C NMR spectra of **23**




Figure S74. ¹H NMR spectra of **24**




Figure S75. ¹³C NMR spectra of **24**




Figure S76. ¹⁹F NMR spectra of **24**




Figure S77. ¹H NMR spectra of 25




Figure S78. ¹³C NMR spectra of 25




Figure S79. ¹H NMR spectra of 26




Figure S80. ¹³C NMR spectra of 26




Figure S81. ¹H NMR spectra of **27**




Figure S82. ¹³C NMR spectra of **27**




Figure S83. ^{19}F NMR spectra of **27**




Figure S84. ^1H NMR spectra of **28**




Figure S85. ^{13}C NMR spectra of **28**




Figure S86. ^1H NMR spectra of **29**




Figure S87. ^{13}C NMR spectra of **29**




Figure S88. ^1H NMR spectra of **30**




Figure S89. ¹³C NMR spectra of 30




Figure S90. ¹H NMR spectra of 31




Figure S91. ^{13}C NMR spectra of **31**




Figure S92. ^1H NMR spectra of **32**




Figure S93. ^{13}C NMR spectra of 32




Figure S94. ^1H NMR spectra of 33




Figure S95. ^{13}C NMR spectra of **33**




Figure S96. ^1H NMR spectra of **34**




Figure S97. ^{13}C NMR spectra of **34**





Figure S98. ^1H NMR spectra of **35**




Figure S99. ¹³C NMR spectra of **35**




Figure S100. ¹H NMR spectra of **36**




Figure S101. ^{13}C NMR spectra of **36**




Figure S102. ^{19}F NMR spectra of **36**




Figure S103. ¹H NMR spectra of **37**




Figure S104. ¹³C NMR spectra of **37**




Figure S105. ¹H NMR spectra of **38**




Figure S106. ¹³C NMR spectra of **38**




Figure S109. ^{19}F NMR spectra of **39**




Figure S110. ^1H NMR spectra of **40**




Figure S111. ¹³C NMR spectra of **40**




Figure S112. ¹H NMR spectra of **41**




Figure S113. ¹³C NMR spectra of **41**




Figure S114. ¹H NMR spectra of **42**




Figure S115. ^{13}C NMR spectra of **42**




Figure S116. ^1H NMR spectra of **43**




Figure S117. ^{13}C NMR spectra of **43**




Figure S118. ^1H NMR spectra of **44**




Figure S119. ^{13}C NMR spectra of **44**




Figure S120. ^1H NMR spectra of **45**




Figure S121. ¹³C NMR spectra of **45**





Figure S122. ¹H NMR spectra of **46**




Figure S123. ^{13}C NMR spectra of **46**




Figure S124. ^{19}F NMR spectra of **46**




Figure S125. ¹H NMR spectra of **47**




Figure S126. ¹³C NMR spectra of **47**




Figure S127. ¹⁹F NMR spectra of **47**




Figure S128. ¹H NMR spectra of **48**






Figure S129. ¹³C NMR spectra of **48**



49

Figure S130. ¹H NMR spectra of **49**




Figure S131. ^{13}C NMR spectra of **49**





Figure S132. ^1H NMR spectra of **50**




Figure S133. ^{13}C NMR spectra of **50**




Figure S134. ^1H NMR spectra of **51**




Figure S135. ¹³C NMR spectra of **51**




Figure S136. ¹H NMR spectra of **52**




Figure S137. ^{13}C NMR spectra of **52**





Figure S138. ^1H NMR spectra of **53**




Figure S139. ¹³C NMR spectra of **53**




Figure S140. ¹⁹F NMR spectra of **53**




Figure S143. ¹H NMR spectra of **55**




Figure S144. ¹³C NMR spectra of **55**




Figure S145. ¹H NMR spectra of **56**




Figure S146. ¹³C NMR spectra of **56**




Figure S147. ¹H NMR spectra of **57**




Figure S148. ¹³C NMR spectra of **57**




Figure S149. ¹H NMR spectra of **58**




Figure S150. ¹³C NMR spectra of **58**




Figure S151. ¹H NMR spectra of **59**




Figure S152. ¹³C NMR spectra of **59**




Figure S153. ¹H NMR spectra of **60**




Figure S154. ¹³C NMR spectra of **60**




Figure S155. ¹H NMR spectra of **61**




Figure S156. ¹³C NMR spectra of **61**




Figure S157. ¹H NMR spectra of **62**




Figure S158. ¹³C NMR spectra of **62**




Figure S159. ¹H NMR spectra of **64**




Figure S160. ¹³C NMR spectra of **64**




Figure S161. ¹H NMR spectra of **65**




Figure S162. ¹³C NMR spectra of **65**




Figure S163. ¹H NMR spectra of **66**




Figure S164. ¹³C NMR spectra of **66**




Figure S165. ¹H NMR spectra of **67**




Figure S166. ¹³C NMR spectra of **67**




Figure S167. ¹H NMR spectra of **68**




Figure S168. ¹³C NMR spectra of **68**




Figure S169. ¹H NMR spectra of **69**




Figure S170. ¹³C NMR spectra of **69**




Figure S171. ^1H NMR spectra of **70**




Figure S172. ^{13}C NMR spectra of **70**




Figure S173. ¹H NMR spectra of 71




Figure S174. ¹³C NMR spectra of 71




Figure S175. ¹H NMR spectra of 72




Figure S176. ¹³C NMR spectra of 72




Figure S177. ¹H NMR spectra of **73**




Figure S178. ¹³C NMR spectra of **73**




Figure S179. ¹H NMR spectra of **74**




Figure S180. ¹³C NMR spectra of **74**

14 References

- [1] Z. X. Xing, S. S. Chen, H. M. Huang, *Org. Lett.* **2024**, 0–5.
- [2] X. W. Chen, C. Li, Y. Y. Gui, J. P. Yue, Q. Zhou, L. L. Liao, J. W. Yang, J. H. Ye, D. G. Yu, *Angew. Chemie - Int. Ed.* **2024**, *63*, 1–8.
- [3] J. L. Tyler, F. Schäfer, H. Shao, C. Stein, A. Wong, C. G. Daniliuc, K. N. Houk, F. Glorius, *J. Am. Chem. Soc.* **2024**, *146*, 16237–16247.
- [4] L. Xiao, Y. Wang, M. Zhang, W. Wu, L. Kong, Y. Ma, X. Xu, X. Liu, Q. He, Y. Qian, H. Sun, H. Wu, C. Lin, H. Huang, R. Ye, S. Jiang, R. F. Ye, C. Yuan, S. Fang, D. Xue, X. Yang, H. Chen, Y. Zheng, L. Yu, Q. Xie, L. Zheng, W. Fu, W. Li, Z. Qiu, J. Liu, L. Shao, *J. Med. Chem.* **2019**, *62*, 11054–11070.
- [5] M. Golfmann, M. Reinhold, J. D. Steen, M. S. Deike, B. Rodemann, C. Golz, S. Crespi, J. C. L. Walker, *ACS Catal.* **2024**, 13987–13998.
- [6] M. Xu, Z. Wang, Z. Sun, Y. Ouyang, Z. Ding, T. Yu, L. Xu, P. Li, *Angew. Chemie - Int. Ed.* **2022**, *61*, DOI 10.1002/anie.202214507.
- [7] Y. Zhang, S. S. Chen, K. D. Li, H. M. Huang, *Angew. Chemie - Int. Ed.* **2024**, e202401671.
- [8] Z. Huang, J. E. Reilly, R. N. Buckle, *Synlett* **2007**, 1026–1030.
- [9] A. Iwanami, S. Komori, Y. Ura, *Chem. Commun.* **2024**, *60*, 7495–7498.
- [10] D. A. V. Oleg G. Kulinkovich* , Sergei V. Sviridov, *Synthesis (Stuttg).* **1991**, *3*, 234.
- [11] X. Pan, H. Wang, C. Li, J. Z. H. Zhang, C. Ji, *J. Chem. Inf. Model.* **2021**, *61*, 3159–3165.
- [12] W. D. Jang, J. Jang, J. S. Song, S. Ahn, K. S. Oh, *Comput. Struct. Biotechnol. J.* **2023**, *21*, 3532–3539.
- [13] L. Kong, X. Shu, S. Tang, R. Ye, H. Sun, S. Jiang, Z. Li, J. Chai, Y. Fang, Y. Lan, L. Yu, Q. Xie, W. Fu, Y. Wang, W. Li, Z. Qiu, J. Liu, L. Shao, *J. Med. Chem.* **2022**, *65*, 10377–10392.